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SAMMANFATTNING 
Bakgrund 
Patienter med akut kranskärlssjukdom (ACS) löper hög risk för allvarliga komplikationer såväl under 
vårdtiden som efter utskrivning från sjukhus. Syftet med detta avhandlingsarbete har varit att 
undersöka faktorer, som kan förutsäga risk för allvarliga händelser såsom rytmrubbningar, hjärtstopp 
och död vid och efter ACS. Vidare har betydelsen av kaliumrubbningar i detta sammanhang 
undersökts. 
Metoder och resultat 
Studie I: Vi använde data från det svenska hjärtsjukvårdsregistret SWEDEHEART för att undersöka 
möjliga prediktorer för hjärtstopp på sjukhus hos patienter med misstänkt NSTE-ACS, den form av 
ACS där kranskärlet vanligen bara är delvis tilltäppt. En riskalgoritm bestående av fem variabler 
(blodtryck, ålder, hjärtfrekvens, EKG-förändring och grad av hjärtsviktssymptom) togs fram. Denna 
validerades genom att använda annan patientdata från SWEDEHEART och MINAP, det brittiska 
hjärtinfarktsregistret.  
Studie II: Genom att länka data från SWEDEHEART och det svenska pacemaker- och ICD-registret 
kunde vi identifiera patienter, som skrivits ut efter hjärtinfarkt, genomgått kranskärlsröntgen under 
vårdtiden och inte hade ICD (inopererad defibrillator). Sambanden mellan kliniska parametrar och 
hjärtstopp utanför sjukhus (OHCA) inom 90 dagar undersöktes genom samkörning med det svenska 
hjärt-lungräddningsregistret. Incidensen av OHCA var lägre (0,29%) än i tidigare studier. Sex 
variabler (kön, ålder, njurfunktion, grad av hjärtsviktssymptom, nyupptäckt förmaksflimmer/-fladder 
och LVEF, d.v.s. andel blod som pumpas ur vänster kammare vid varje hjärtslag) var oberoende 
associerade med OHCA. Dessa variabler predicerade också risk för död inom 90 dagar hos patienter, 
som inte registrerats i det svenska hjärt-lungräddningsregistret under samma tidsperiod. Ovannämnda 
variabler förutsade risken för OHCA bättre än endast LVEF, som enskilt fortfarande är den mest 
använda riskmarkören. 
Studie III: Patienter som lagts in på sjukhus på misstanke om ACS och som registrerats i 
SWEDEHEART och SCREAM inkluderades i denna studie. SCREAM är ett register, som samlat 
laboratoriedata avseende njur- och saltprover från alla patienter, som genomgått dylik provtagning i 
Stockholm. Sambanden mellan kaliumnivå vid inskrivning och utfall under sjukhusvistelsen 
undersöktes. Hyperkalemi (förhöjt kalium) var associerat med risk för död medan hypokalemi (för 
lågt kalium) var associerat med risk för hjärtstopp och nyupptäckt förmaksflimmer-/fladder. Dessa 
samband påverkades inte av huvuddiagnos vid utskrivning (typ av ACS eller annan icke-ACS-
diagnos) eller kliniska parametrar vid ankomst till sjukhus.  
Studie IV: Även i denna studie användes data från SWEDEHEART och SCREAM. Patienter som 
skrivits ut efter hjärtinfarkt inkluderades. Sambanden mellan kaliumnivå vid utskrivning och diverse 
utfall under följande år undersöktes. Kaliumnivå och njurfunktion vid utskrivning förutsade risken för 
kaliumrubbningar under det följande året, vilka drabbade knappt 37% av patienterna. Ett U-format 
samband sågs mellan kaliumnivå vid utskrivning och risk för död inom ett år. 
Slutsats 
En riskalgoritm bestående av fem variabler kan underlätta riskbedömningen avseende hjärtstopp på 
sjukhus för patienter som inläggs på misstanke om ACS. Incidensen av OHCA inom 90 dagar efter 
hjärtinfarkt var i vår studie lägre än tidigare visat. Sex variabler inklusive LVEF förutsade risken för 
OHCA bättre än vad LVEF för sig gjorde. Kaliumrubbningar vid inkomst är associerade med 
allvarliga rytmrubbningar och död under sjukhustiden hos patienter som läggs in på misstanke om 
ACS oavsett slutdiagnos och inkomstparametrar. Kaliumrubbningar inom första året efter hjärtinfarkt 
är vanligt förekommande och prediceras av njurfunktion och kaliumnivå vid utskrivning, vilka också 
predicerar död inom ett år.  
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ABSTRACT 
Background 
Patients with acute coronary syndrome (ACS) face a high risk of lethal complications, both 
during the hospital course and after discharge. The aim of this thesis was to assess patient 
characteristics and predictors of adverse events in ACS including arrhythmias, cardiac arrest, 
and mortality as well as the impact of potassium disorders in this setting. 
Methods and results 
Study I: We used data from the Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart disease Evaluated According to Recommended Therapies 
(SWEDEHEART) to assess predictors of in-hospital cardiac arrest in patients admitted with 
suspected non-ST-elevation ACS (NSTE-ACS). A risk-score model was developed including 
five variables: systolic blood pressure <100 mmHg, age ≥60 years, heart rate <50 or ≥100 
bpm, ST-T abnormalities on the admission ECG, and Killip class ≥II. The risk-score model 
was temporally validated in SWEDEHEART and externally validated using data from the 
Myocardial Ischaemia National Audit Project (MINAP). 
Study II: Using SWEDEHEART and the Swedish Pacemaker and Implantable Cardioverter-
Defibrillator (ICD) Registry, we identified patients without a prior ICD, who had undergone 
in-hospital coronary angiography and were discharged alive after myocardial infarction (MI). 
Associations between patient characteristics and out-of-hospital cardiac arrest (OHCA) as 
recorded in the Swedish Cardiopulmonary Resuscitation Registry within 90 days after 
discharge were assessed. The incidence of OHCA was low (0.29%) compared to previous 
studies. Six variables (male sex, age ≥60 years, estimated glomerular filtration rate [eGFR] 
<30 mL/min per 1.73 m2, Killip class ≥II, new-onset atrial fibrillation/flutter, and LVEF 
categorized as ≥50%, 40-49%, 30-39%, and <30%) were independently associated with 
OHCA and predicted OHCA as well as non-OHCA death better than an LVEF cut-off of 
<40% alone. 
Study III: Patients admitted with suspected ACS and registered in SWEDEHEART and the 
Stockholm CREAtinine Measurements (SCREAM) project were included. Associations 
between admission plasma potassium and in-hospital outcomes were assessed. In fully 
adjusted models, hyperkalemia was associated with mortality, while hypokalemia was 
associated with cardiac arrest and new-onset atrial fibrillation. No association was observed 
between potassium and second- or third-degree atrioventricular block. Results were not 
modified by discharge diagnosis (ACS subtype or non-ACS diagnosis) or baseline 
characteristics. 
Study IV: SWEDEHEART and SCREAM were used to identify patients discharged alive 
after MI. Associations between plasma potassium at discharge and outcomes within one year 
were assessed. Potassium and eGFR at discharge were found to be independent predictors of 
hyper- or hypokalemia within one year, which affected 36.5% of the patients. A U-shaped 
association was observed between discharge potassium and mortality within one year.  
Conclusion 
A five-variable risk score can be used to predict in-hospital cardiac arrest in patients admitted 
with suspected ACS. In a contemporary cohort of MI patients, the incidence of OHCA within 
90 days after discharge was low, but compared to an LVEF cut-off alone which is routinely 
used, five variables in addition to LVEF predicted OHCA better. Dyskalemias at admission 
are associated with in-hospital arrhythmic events and mortality across all ACS/non-ACS 
diagnoses regardless of baseline characteristics. Potassium disorders within the first year 
following MI are frequently encountered and potassium level and kidney function at 
discharge strongly predict their occurrence as well as one-year mortality.  
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1 INTRODUCTION 
The term acute myocardial infarction (MI) defines a clinical or pathologic event consistent 
with acute myocardial ischemia, where there is proof of myocardial necrosis. In a clinical 
setting, a typical rise and/or fall in biomarkers of myocyte injury (ideally cardiac troponin) 
with at least one value above the 99th percentile upper reference limit is mandatory for the 
diagnosis1. Acute coronary syndrome (ACS) refers to the clinical spectrum of presentation of 
acute myocardial ischemia and includes ST-elevation MI (STEMI), non-ST-elevation MI 
(NSTEMI), and unstable angina (UA), where the latter is not accompanied by myocardial 
necrosis. NSTEMI and UA are jointly termed NSTE-ACS2. 
Rates of morbidity and mortality associated with ischemic heart disease have declined 
considerably during the last decades, much owing to the earlier and more widespread use of 
coronary revascularization, more aggressive antithrombotic treatment, and secondary 
preventive medication3-6. Furthermore, there has been a change in pattern of ACS with a 
transition from STEMI to NSTE-ACS, which has now become predominant7. Nevertheless, 
ACS is still a leading global cause of morbidity and mortality. A better understanding and 
reconsideration of risk factors associated with adverse events in ACS is therefore warranted8. 
The following sections outline certain aspects of risk in ACS covered in the thesis. 
1.1 MECHANISMS AND TEMPORAL DISTRIBUTION OF VENTRICULAR 
ARRHYTHMIAS IN ACUTE CORONARY SYNDROME 
In the setting of ACS, ventricular arrhythmias, including sustained ventricular tachycardia 
(VT) and ventricular fibrillation (VF), are a potentially life-threatening complication that can 
occur both in the acute phase and during the course of follow-up. Ventricular arrhythmias can 
be thought to result from the interaction between three basic components: substrate, trigger, 
and modulating factors. These components and hence the electrophysiological mechanisms of 
arrhythmia vary during the time course of ischemia. The functional changes within the 
injured myocardium set the stage for the arrhythmogenic substrate. In order for arrhythmias 
to become manifest, appropriate trigger factors such as ventricular premature depolarization, 
variations in cycle length, and heart rate must be present. Additionally, modulating factors 
including electrolyte abnormalities, e.g. potassium disturbances (see Section 1.2), impaired 
left ventricular function, and altered sympathetic nervous system activity may modify the 
substrate as well as the trigger9. 
Much of our knowledge about ischemia-related arrhythmia mechanisms is derived from 
experimental studies. A distinction is made between phase 1, the early and potentially 
reversible stage within 2 to 30 minutes of ischemia, and phase 2, the infarct-evolving phase 
starting about 1.5-5 hours after ischemia onset and lasting up to 48-72 hours. Phase 1 is 
further divided into phases 1A (2-10 minutes) and 1B (15-30 minutes). Phase 1A arrhythmias 
are thought to arise mainly from reentry that causes bursts of VT, which rarely degenerates 
into VF. Arrhythmias during phase 1B may involve both automatic and non-automatic 
ectopic excitation as well as reentry, resulting in VT and more frequently VF, as opposed to 
Predictors of Arrhythmias, Cardiac Arrest, and Mortality in Acute Coronary Syndrome 
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phase 1A. It has been proposed that phase 2 arrhythmias are associated with reperfusion of 
ischemic areas and share mechanisms similar to those seen in phase 1B. Surviving Purkinje 
fibers displaying abnormal automaticity are believed to be among the specific foci underlying 
arrhythmia in phase 210. Ventricular arrhythmias occurring beyond phase 2 (>72 hours) are 
usually scar mediated and give rise to monomorphic VT caused by reentry, which is 
facilitated by slow conduction in fibrotic areas of infarcted myocardial tissue11. Polymorphic 
VT has been reported to occur infrequently after myocardial infarction and may be associated 
with signs or symptoms of recurrent ischemia12. Figures 1 and 2 outline temporal 
distribution, biochemical, and electrophysiological characteristics of ischemic ventricular 
arrhythmias in more depth 
 
Figure 1. Temporal distribution and genesis of ischemic ventricular arrhythmias10. 
Reproduced with permission from Elsevier. 
VT: ventricular tachycardia; VF: ventricular fibrillation; AA: abnormal automaticity; EADs: Early 
afterdepolarizations; DADs: Delay afterdepolarizations (DADs); P2R: phase 2-reentry; PFs: Purkinje fibers. 
 
Figure 2. Biochemical and electrophysiological characteristics of Phase 1 and Phase 2 
ischemia mediated ventricular arrhythmias10. Reproduced with permission from Elsevier . 
INa: sodium channel current; Late INa: late INa; APD: action potential duration; ICa: inward calcium current; 
IK-ATP: ATP-sensitive potassium current. 
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1.2 ELECTROPHYSIOLOGICAL EFFECTS OF POTASSIUM DISORDERS 
The ratio of intra- and extracellular potassium concentrations is critical for the resting 
membrane potential and for generating action potentials in the heart and other excitable 
tissues. Approximately 98% of total body potassium is distributed as an intracellular cation, 
whereas only a small portion is extracellular with plasma levels normally strictly maintained 
between 3.5 and 5.0 mmol/L13. Potassium derangements impact on electrophysiological 
properties and promote arrhythmias through the interplay between K+, Na+, and Ca2+, and the 
regulation of the Na+-K+ ATPase and Na+-Ca2+ exchange.  
Hypokalemia causes hyperpolarization of the resting membrane, inhibits the Na+-K+ ATPase, 
and suppresses K+ channel conductance. This, in turn, results in action potential duration 
(APD) prolongation, reduced repolarization reserve, early afterdepolarization (EAD), delayed 
afterdepolarization (DAD), and automaticity. EAD-mediated arrhythmias include Torsades 
de pointes and polymorphic VT, which may degenerate to VF. Additionally, hypokalemia 
enhances the proarrhythmic effect of class III antiarrhythmic drugs (K+ channel blockers) by 
further suppressing K+ channel conductance and may also increase the affinity of the drug14.  
Some observational data have suggested a possible association between hypokalemia and 
atrial fibrillation15, 16. An experimental study demonstrated that hypokalemia reduces 
sinoatrial node automaticity and induces triggered activity and burst firing in pulmonary 
veins, which may play a role in the genesis of atrial fibrillation17. 
Systemic hyperkalemia enhances K+ channel conductance, shortens APD, and induces post-
repolarization refractoriness, resulting in increased repolarization reserve. Furthermore, the 
resting membrane potential depolarizes, which alters conduction velocity (CV) in a biphasic 
manner. Initially CV accelerates but then gradually becomes slower as hyperkalemia 
progresses. Nonetheless, hyperkalemia causes CV restitution, i.e. the dependence of the CV 
of a propagating wave on the preceding diastolic interval, to accentuate. Arrhythmias 
resulting from hyperkalemia include asystole, heart block, and VT/VF, where reentry may be 
induced by several mechanisms. The severity of hyperkalemia needed to induce arrhythmias 
varies substantially among humans. The sinus node and sinoatrial conduction are generally 
less sensitive to hyperkalemia than the atrioventricular (AV) node and infranodal escape 
pacemakers14.  
Interstitial hyperkalemia defines a rise of interstitial [K+] in tissue with normal [K+] in the 
systemic circulation. Interstitial [K+] increases swiftly in the central ischemic zone after acute 
coronary occlusion. APD shortens and the resting membrane potential depolarizes resulting 
in systolic and diastolic injury currents flowing across the border zone, which can reexcite 
nonischemic recovered tissue to generate extrasystoles promoting reentry. Additionally, 
phase 2 reentry (reentry not depending on circus movement, where local reexcitation is 
generated in a region with spatially widely dispersed repolarization18) may arise from the 
subepicardium14. All together, these changes set the stage for both triggers and substrates 
Predictors of Arrhythmias, Cardiac Arrest, and Mortality in Acute Coronary Syndrome 
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capable of inducing ventricular ectopy, VT, and VF during phase 1 of acute myocardial 
ischemia14. 
1.3 IN-HOSPITAL CARDIAC ARREST AND RHYTHM MONITORING IN NON-ST 
ELEVATION ACUTE CORONARY SYNDROME 
In patients with STEMI, in-hospital ventricular arrhythmias affect approximately 5% and 
most commonly occur within the first 48 hours19-21. In NSTE-ACS, in-hospital ventricular 
arrhythmias are less common. A pooled analysis of four major randomized controlled trials 
(RCTs) with over 26,000 patients conducted in the 1990s showed that the incidence of in-
hospital ventricular arrhythmias was 2.1%. Median time to arrhythmia was approximately 78 
hours and its occurrence was associated with increased mortality at 30 days and six months. 
Prior hypertension, chronic obstructive pulmonary disease, prior myocardial infarction, and 
the presence of ST-segment changes at presentation were associated with VF, and the same 
variables except for hypertension also predicted VT (Table 1)22. In a more recent substudy of 
the Early Glycoprotein IIb/IIIa Inhibition in NSTE-ACS (EARLY ACS) trial, comprising 
9211 patients, in-hospital ventricular arrhythmias occurred in 1.5% and were associated with 
increased mortality after discharge, both at 30 days and at one year. In-hospital ventricular 
arrhythmias were as likely to occur after 48 hour as within 48 hours and in 38% of affected 
patients they occurred after revascularization. Eight factors were independently associated 
with in-hospital ventricular arrhythmias (Table 1). Higher systolic blood pressure and higher 
estimated creatinine clearance were associated with a lower risk of in-hospital ventricular 
arrhythmias. Higher white blood cell count, higher heart rate, and higher body weight were 
associated with higher risk of in-hospital ventricular arrhythmias as were elevated baseline 
troponin level, Killip class higher than I, and a history of angina23. A single-center study of 
588 NSTEMI patients reported a 2.6% incidence of in-hospital ventricular arrhythmias where 
two-thirds occurred within 12 hours of onset of symptoms24. In a more recent single-center 
study of 1325 patients with NSTEMI, the incidence of in-hospital ventricular arrhythmias 
was 1.5% (n=21) and approximately 25% occurred after 48 hours of hospitalization25. This 
study also reported that risk stratification at admission using the Global Registry of Acute 
Coronary Events (GRACE) score26, 27 and echocardiographic systolic left ventricular ejection 
fraction (LVEF) could identify NSTEMI patients with a higher risk for in-hospital ventricular 
arrhythmias25. 
Patients with ACS are also at risk for in-hospital non-VT/VF cardiac arrest, i.e. asystole and 
pulseless electrical activity (PEA), as well as high-degree AV block. In a pooled analysis of 
three large RCTs comprising nearly 30,000 patients with NSTEMI, asystole or PEA occurred 
in 0.7% and was more frequent beyond the first 48 hours. High-degree AV block affected 
0.4% and was more common within the first 48 hours. Increasing age, higher heart rate, 
higher Killip class, ST-segment depression on admission, prior myocardial infarction, and 
prior peripheral artery disease were associated with both asystole and PEA. Older age, lower 
heart rate, lower blood pressure, and prior diabetes were associated with high-degree AV-
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block, which was also more commonly observed in patients with right coronary artery 
lesions28.  
For patients admitted with confirmed or suspected NSTE-ACS, decisions have to be made 
regarding level of surveillance including selection of patients for and duration of continuous 
ECG monitoring. Current guidelines (2014) from the American College of Cardiology (ACC) 
and the American Heart Association (AHA) provide several clinical factors that have been 
found to be predictive of VT/VF (Table 1): heart failure signs on presentation, hypotension, 
tachycardia, cardiogenic shock, and poor Thrombolysis in Myocardial Infarction (TIMI) 
flow29. Current guidelines (2015) from the European Society of Cardiology (ESC) 
recommend monitoring in low-risk patients until revascularization or ≤24 hours, and 
prolonged monitoring only if intermediate/high-risk features are present (e.g. hemodynamic 
instability, major arrhythmias, LVEF <40%, failed reperfusion and the presence of critical 
stenosis or complications related to percutaneous coronary intervention [PCI])2. According to 
ESC guidelines, continuous rhythm monitoring is also recommended until the diagnosis of 
NSTE-ACS is established or ruled out2 and this is supported by a consensus document from 
AHA with expert opinions from 200430. 
Table 1. Predictors of in-hospital VT/VF in NSTE-ACS. 
Al-Khatib et al.22  Piccini et al.23  Amsterdam et al.29 
Prior hypertension* Lower systolic blood pressure Signs of HF on presentation 
COPD Lower creatinine clearance Hypotension 
Prior MI Elevated troponin Tachycardia 
ST-changes at presentation Killip class ≥II Cardiogenic shock 
 Higher WBC Low TIMI flow grade 
 Higher heart rate  
 Higher body weight  
 History of angina  
*Only associated with VF; COPD: chronic obstructive pulmonary disease; TIMI: Thrombolysis in Myocardial 
Infarction; WBC: white blood cell count; HF: heart failure. 
In summary, several studies have investigated incidence, timing and prognosis of in-hospital 
ventricular arrhythmias and also non-VT/VF cardiac arrest in the setting of NSTE-ACS. 
However, the best data come from subanalyses of large multicenter trials, which refer to 
selected patients and do not necessarily reflect real-life clinical practice. Current guidelines 
suggest several risk factors associated with in-hospital ventricular arrhythmias and also 
provide recommendations for duration of continuous ECG-monitoring but these are mainly 
based on experts’ opinions. 
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1.4 CARDIAC ARREST AND SUDDEN CARDIAC DEATH AFTER 
MYOCARDIAL INFARCTION DISCHARGE 
Following MI, patients are at increased risk for sudden cardiac death (SCD), which is largely 
due to ventricular tachyarrhythmias and subsequent cardiac arrest31. The 30-day cumulative 
incidence of SCD was 1.2% in a community cohort of nearly 3000 post-MI patients between 
1979 and 2005, while the event rate after 30 days declined to 1.2% per year during a median 
follow up of 4.7 years32. In a study comprising over 14,000 post-MI patients between 1998 
and 2001 with LVEF ≤40% or clinical or radiologic evidence of heart failure, the risk of SCD 
or resuscitated cardiac arrest was 1.4% in the first month and fell to 0.14% per month after 
two years. Restricted to patients with LVEF ≤30%, the event rate in the first month was 
2.3%. Notably, among patients with cardiac arrest within the first month and successful 
resuscitation, 74% were still alive at 12 months33. Despite the increased risk of SCD in the 
early phase after MI, two major randomized trials conducted between 1998 and 2007 did not, 
due to competing causes of death, demonstrate improved survival for patients with LVEF 
≤35% and ≤30%, respectively, randomly assigned to receive an implantable cardioverter-
defibrillator (ICD) within 31 to 40 days (at a mean of 18 and 13 days respectively) after 
MI34, 35. Hence, current guidelines recommend ICD for primary prevention at least 40 days 
after MI and 90 days after revascularization in patients with LVEF ≤35% and symptomatic 
heart failure, New York Heart Association (NYHA) class II-III, or LVEF ≤30%, on optimal 
medical therapy for ≥3 months36, 37. These guidelines primarily rely on two RCTs 
demonstrating superior long-term survival for patients who received an ICD more than 30 
days after MI with LVEF ≤30%38 or after at least three months of optimal medical therapy 
with symptomatic heart failure (NYHA II-III) and LVEF ≤35%39. Several non-invasive tests 
for early risk stratification, such as microvolt T-wave alternans, tests for autonomic 
dysfunction, or signal-averaged electrocardiogram, have been proposed but without 
convincing evidence40-42. Thus, according to current European guidelines, non-invasive tests 
in the early post-MI phase are not recommended (class III). Instead, LVEF should be 
reevaluated 6 to 12 weeks (class I) after MI to assess indication for primary prevention ICD 
implantation36. 
Some data support that an electrophysiology study (EPS) with no inducible sustained 
ventricular tachyarrhythmias early after MI in patients with LVEF ≤40% is associated with a 
low long-term risk of SCD43-45. Two fairly recent non-randomized single-center studies have 
also demonstrated the use of EPS to guide early ICD therapy in patients with STEMI and 
LVEF ≤40%. An ICD was implanted before discharge in patients with inducible VT at EPS 
performed at a median of 9 days after MI. ICD patients had high rates of spontaneous 
ventricular arrhythmias and a non-negligible proportion received appropriate therapies early 
post-MI: 17% within 2 months post-MI and 25% within 40 days post-MI, respectively. The 
non-ICD patients had a low mortality rate during follow-up (≥30 months)46, 47. Current 
European guidelines suggest that EPS with programmed ventricular stimulation may be 
considered early post-MI in patients with LVEF <40% but also stress that randomized trials 
are needed to evaluate the role of EPN in early risk stratification after MI36. 
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The recently published Vest Prevention of Early Sudden Death Trial (VEST) enrolled 2302 
post-MI patients with LVEF ≤35%. Participants were randomly assigned to a wearable 
cardioverter–defibrillator in a 2:1 ratio within 7 days after MI-discharge and followed up to 
90 days. The cumulative incidences of arrhythmic death and non-arrhythmic death were 1.6% 
and 1.4% in the device group and 2.4% and 2.2% in the control group. The primary outcome 
of arrhythmic death did not differ significantly between the device and control groups48.  
In summary, the risk of ventricular tachyarrhytmias and subsequent SCD is markedly 
increased in the early period following MI. However, current evidence only supports 
primary-preventive ICD implantation at least 40 days after MI. Several non-invasive tests for 
early risk stratification have been suggested but not been proven useful. Further studies are 
needed to support the use of EPN in this setting. Current knowledge and guidelines are 
mainly based on studies conducted in the late 1990s and early 2000s even though 
demographics and treatment of MI-patients have changed. 
1.5 POTASSIUM IMBALANCE AND IN-HOSPITAL OUTCOMES IN ACUTE 
CORONARY SYNDROME 
A number of older observational studies have reported an association between hypokalemia 
and ventricular arrhythmias in patients with acute MI49-57 or suspected but not confirmed 
MI51, 56. However, these studies were all conducted before beta-blockers and reperfusion 
therapy were routinely used and results were mainly based on unadjusted analyses of small 
case series. Hypokalemia was most often defined as serum potassium below 3.6 or 3.5 
mEq/L49-57. 
Data from the Gruppo Italiano per lo Studio delia Sopravvivenza nell'Infarto Miocardico-2 
(GISSI-2) trial, a multicenter, randomized, open trial comparing two thrombolytic agents, 
where all patients without contraindications were treated with intravenous beta-blockers, was 
used to investigate incidence, prognosis and predictors of in-hospital VF. This study 
comprised 9720 patients with STEMI. Multivariate logistic regression analyses, including 
serum potassium level, systolic blood pressure, smoking status, number of ECG leads with 
ST elevation, age, infarct site, admission heart rate, sex, and a history of previous angina, 
showed that serum potassium <3.6 mEq/L was independently associated with early (within 
the first 4 hours) VF (odds ratio [OR] 1.97, confidence interval [CI] 95% 1.51-2.56)58. 
Based on the above mentioned knowledge, guidelines and expert recommendations from the 
early 2000s suggested maintaining serum potassium at a level greater than or equal to 4.0 
mEq/L59, 60 or even above 4.5 mEq/L61 in the setting of MI. These recommendations 
remained unquestioned for several years but were challenged by Goyal and colleagues in 
201262.  
Goyal et al. investigated the association between serum potassium levels, in-hospital 
mortality, and the composite of in-hospital VF or cardiac arrest. The cohort comprised 38,689 
patients with MI from 67 US hospitals between 2000 and 2008. A U-shaped relationship 
between mean post-admission serum potassium level and mortality was observed. Potassium 
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levels <3.5 and ≥4.5 mEq/L were associated with increased mortality. This association 
remained after multivariable adjustment including demographics, comorbidities, first 
measurement during hospitalization of several laboratory values including estimated 
glomerular filtration rate (eGFR) and potassium, presence of cardiogenic shock and acute 
respiratory failure on admission, interventional procedures during hospitalization, and 
medication during hospitalization. When considering serum potassium level at admission 
only, the association was attenuated. After multivariable adjustment, admission potassium 
levels <3.0 and ≥5.0 mEq/L were significantly associated with increased in-hospital 
mortality. For the composite of VF and cardiac arrest, the relationship with mean post-
admission serum potassium level was flatter. Increased rates of VF or cardiac arrest were 
only observed at post-admission serum potassium levels <3.0 and ≥5.0 mEq/L. For serum 
potassium at admission, increased rates of VF or cardiac arrest were only observed at 
potassium levels <3.5 mEq/L62. 
Another study based on the same cohort of MI-patients specifically addressed hyperkalemia 
during hospitalization. Hyperkalemic events (any serum potassium ≥5.0 mEq/L during 
hospitalization) were common and affected 22.6% of patients on dialysis and 66.8% of 
patients not on dialysis. In-hospital mortality surpassed 15% when maximum potassium was 
≥5.5 mEq/L. The association between higher maximum potassium level and increased in-
hospital mortality remained after multivariable adjustment. In-hospital mortality also 
increased with the number of hyperkalemic events63. 
A number of studies after Goyal et al. have demonstrated that both hypo- and hyperkalemia 
are associated with adverse outcomes, primarily increased mortality, in the setting of ACS. 
Choi et al. reported an association between mean serum potassium levels >4.5 and <3.5 
mEq/L during hospitalization and increased long-term mortality (up to three years) in patients 
with MI64. Another study also demonstrated that serum potassium >4.5 and <3.5 mEq/L at 
admission was associated with increased long-term mortality in patients with ACS65. 
Additionally, several studies have showed that potassium imbalance during hospitalization is 
associated with worse outcome in cohorts of patients with NSTE-ACS and STEMI 
exclusively66, 67. 
A recent meta-analysis included twelve studies to assess associations between serum 
potassium concentrations and short and long-term mortality as well as ventricular 
arrhythmias. Short and long-term mortality were defined as all-cause mortality within or 
beyond 6 months. Using serum potassium 3.5-<4.0 mEq/L as the reference category, pooled 
results demonstrated a significantly increased risk for both short and long-term mortality in 
patients with serum potassium concentrations of <3.5 mEq/L and ≥4.5 mEq/L. Moreover, 
serum potassium <3.5 mEq/L was significantly associated with the risk of ventricular 
arrhythmias. Additional analyses were conducted separating studies using admission and 
mean serum potassium concentrations. Both groups of studies showed a significant 
association between serum potassium <3.5 mEq/L and ventricular arrhythmias. However, for 
serum potassium ≥5.0 mEq/L, a significantly increased pooled OR was only seen in studies 
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with a mean serum potassium measurement. In contrast, studies with admission serum 
potassium measurement showed a significantly decreased pooled OR.Since several studies 
used different effect sizes or reference categories, unadjusted, instead of confounder-adjusted, 
estimates were used from some of the studies in the meta-analyses. Hence, and as also 
stressed by the authors, the pooled effects may have been overestimated68.  
In summary, potassium imbalance has been associated with in-hospital ventricular 
arrhythmias and mortality in the setting of ACS. Although this has been shown for ACS in 
general as well as for NSTE-ACS and STEMI separately, no direct comparison between 
different subtypes of ACS has been performed. Furthermore, prior studies have not 
considered important baseline characteristics such as blood pressure, heart rate, or Killip 
class. 
1.6 POTASSIUM IMBALANCE AND OUTCOMES AFTER MYOCARDIAL 
INFARCTION DISCHARGE 
Potassium imbalance is a common clinical problem and is associated with the risk of adverse 
events. Hyperkalemia is more prevalent among patients with chronic kidney disease (CKD), 
diabetes, cardiovascular disease, heart failure, and users of medication such as renin 
angiotensin aldosterone system (RAAS) inhibitors and non-steroidal inflammatory drugs69. 
Hypokalemia is most frequently caused by drugs, primarily diuretic therapy70. A US study 
comprising over 15,000 individuals from the general population aged 44 to 66 years with 
eGFR of at least 60 mL/min/1.73 m2, reported that nearly 5% had serum potassium values of 
<3.5 or ≥5.5 mmol/L in blood samples drawn at baseline between 1987 and 1989. Compared 
to those with normokalemia, a majority of individuals with hypokalemia were taking 
potassium-wasting diuretics (17.7% vs. 9.9%). The use of angiontensin-converting enzyme 
inhibitors (ACEi) did not differ between individuals with normokalemia and potassium 
imbalance71. A retrospective analysis with data from laboratory visits of nearly 16,000 
patients with cardiovascular disease defined as heart failure and hypertension treated with 
antihypertensive drugs showed that 24.5% had hyperkalemia (serum potassium ≥5.0 mEq/L). 
There were no differences in the use of ACEi, angiotensin II receptor blockers (ARBs), or 
potassium-sparing diuretics between normokalemic and hyperkalemic patients. Diabetes, 
CKD stage, coronary artery disease, and peripheral vascular diseased were predictors of 
hyperkalemia. Hyperkalemia was associated with increased all-cause mortality and 
hospitalization72. 
Patients with MI have multiple risk factors for potassium imbalance given a high burden of 
comorbidities such as diabetes, hypertension, heart failure, and CKD. In addition, 
recommended treatment after MI includes medication that may alter potassium levels, 
primarily RAAS inhibitors and diuretics. 
Data on post-discharge potassium levels and associated outcomes following MI are scarce. 
Major randomized clinical trials on treatment with RAAS inhibitors after MI have provided 
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little information about potassium disorders. Furthermore, patients with renal failure, not 
uniformly defined, were often excluded. 
GISSI-3 and the International Study of Infarct Survival-4 (ISIS-4) investigated the effects of 
short-term ACEi therapy (4-6 weeks) after MI but did not report data on potassium 
levels73, 74. Neither did the Survival and Ventricular Enlargement (SAVE) trial nor the Acute 
Infarction Ramipril Efficacy (AIRE) trial, two large RCTs on long-term ACEi treatment 
following MI with heart failure, present information about potassium disturbances75, 76. The 
Trandolapril Cardiac Evaluation (TRACE) trial, another study where patients with heart 
failure after MI were assigned long-term ACEi therapy, reported that hyperkalemia (not 
defined in terms of specific biochemical values) occurred in 4.9% compared to 2.6% in the 
placebo group77. The Optimal Trial in Myocardial Infarction with the Angiotensin II 
Antagonist Losartan (OPTIMAAL) compared ACEi to ARB treatment in patients after MI 
associated with heart failure. Data on potassium disorders were not reported but serum 
potassium differed significantly between baseline and study end (mean follow-up 2.7 years) 
in the two treatment arms with an increase by approximately 0.2 mmol/L78. In the VALIANT 
trial, patients with heart failure after MI were assigned to ACEi, ARB, or both. Hyperkalemia 
was not specified but was reported to result in dose reduction in 0.9-1.3% in the three 
treatment arms whereas hyperkalemia resulting in permanent discontinuation occurred in 0.1-
0.2%79. The EPHESUS trial investigated the effects of eplerenone, a mineralocorticoid 
receptor antagonist (MRA) vs. placebo when added to optical medical therapy including 
ACEi/ARB (87%), beta-blockers (75%), and diuretics (60%) in patients with heart failure 
following MI. Mean follow-up was 16 months. Serious hypokalemia defined as serum 
potassium <3.5 mmol/L was observed in 8.4% in the eplerenone group and 13.1% in the 
placebo group. Serious hyperkalemia defined as serum potassium ≥6.0 mmol/L was observed 
in 5.5% in the eplerenone group and in 3.9% in the placebo group80. 
A Danish registry-based study of 2596 patients receiving diuretics following hospitalization 
for MI reported increased all-cause mortality at 90 days for those with serum potassium <3.5 
mmol/L and >5.0 mmol/L post-discharge. Increased mortality was also observed for serum 
potassium levels within the lower and upper normal ranges (3.5-3.8 and 4.6-5.0 mmol/L). 
These associations remained after multivariable adjustment including comorbidities and 
medication (RAAS inhibitors included). However, the models were not adjusted for renal 
function and patients with CKD before index MI were excluded from the study81. 
Table 2 summarizes the abovementioned trials. 
In summary, comorbidities and medication are contributing risk factors to potassium 
disorders after MI discharge. Potassium levels and associated outcomes have rarely been 
reported in the major RCTs on RAAS inhibitors post-MI and real-world data on this matter 
are also lacking. 
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Table 2. Major randomized controlled trials on renin-angiotensin-aldosterone system 
inhibitors following myocardial infarction. 
Trial Intervention 
drug 
Exclusion for 
renal 
impairment 
Method of K 
measurement 
Hypokalemia Hyperkalemia 
EPHESUS80 
N=6642. AMI 
within 3-14 
days. LVEF 
<40% after 
index MI. 
Symptoms of 
HF or non-
symptomatic if 
concomitant 
diabetes. Mean 
follow-up 16 
months. 
Eplerenone vs. 
placebo added 
to optical 
medical 
therapy: 
ACEi/ARBs 
(87%), beta-
blockers (75%), 
diuretics (60%). 
Serum 
creatinine > 220 
µmol/L (2.5 
mg/dL) 
Serum 
potassium 
Severe 
hypokalemia 
(<3.5 mmol/L): 
Eplerenone 
(8.4%), 
Placebo 
(13.1%) 
Serious 
hyperkalemia 
(≥6.0 mmol/L): 
Eplerenone 
(5.5%), 
Placebo (3.9%) 
 
VALIANT79 
N=14,703. AMI 
within 0.5-10 
days. Clinical or 
radiological 
signs of HF, 
LVEF <35% 
(TTE) or <40% 
(nuclear 
imaging). Mean 
follow-up 24.7 
months. 
 
Valsartan or 
valsartan + 
captopril vs. 
captopril alone. 
Beta-blockers 
(70%), 
potassium-
sparing 
diuretics (9%), 
other diuretics 
(50%). 
Serum 
creatinine > 221 
µmol/L (2.5 
mg/dL) 
Hyperkalemia, 
increased blood 
potassium level, 
was 
investigator-
reported and not 
defined in terms 
of specific 
biochemical 
values.  
 
Not specified Resulting in 
dose reduction: 
valsartan 
(1.3%), 
valsartan+ 
captopril 
(1.2%), 
captopril (0.9%) 
Resulting in 
permanent 
discontinuation: 
Valsartan 
(0.1%), 
valsartan+ 
captopril 
(0.2%), 
captopril (0.1%) 
OPTIMAAL78 
N=5477. AMI 
during the acute 
phase (new 
anterior Q-wave 
AMI, any AMI 
with previous 
anterior Q-
waves, or any 
AMI with heart 
failure). Mean 
follow-up 2.7 
years. 
Captopril vs. 
losartan. Beta-
blockers 
(78.6%), 
diuretics 
(63.8%), 
digitalis 
(11.2%). 
Not specified Serum 
potassium 
Not specified Not specified. A 
significant 
difference 
between 
baseline and 
study end was 
observed 
(increase of 
0.19-0.22 
mmol/L). 
ISIS-474 
N=58,050. 
Suspected AMI 
(92% 
confirmed) with 
symptom onset 
within 24 h. 5-
week follow-up. 
Captopril vs. 
placebo 
Not specified Not specified Not specified Not specified 
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Table 2. Major randomized controlled trials on renin-angiotensin-aldosterone system 
inhibitors following myocardial infarction (continued). 
Trial Intervention 
drug 
Exclusion for 
renal 
impairment 
Method of K 
measurement 
Hypokalemia Hyperkalemia 
GISSI-373 
N=18,895. AMI 
with symptom 
onset within 24 
h. 6-week 
follow-up. 
Lisinopril vs. 
controls. 
Serum 
creatinine > 177 
µmol/L, 
proteinuria 
>500 mg per 24 
h, or both. 
Bilateral 
stenosis of the 
renal arteries. 
Not specified Not specified Not specified 
TRACE77 
N=1749. AMI 
within 3-7 days. 
LVEF ≤35%. 
24-50 months of 
follow-up. 
Trandolapril vs. 
placebo. Beta-
blockers (16%), 
diuretics (66%), 
digoxin/ 
digitalis (27%). 
Serum 
creatinine ≥ 200 
µmol/L (2.3 
mg/dL) 
Not specified Not specified Trandolapril 
(4.9%), placebo 
(2.6%) 
AIRE76 
N=2006. AMI 
within 3-10 
days. Clinical 
evidence of 
heart failure. 
Mean follow-up 
15 months. 
Ramipril vs. 
placebo. Beta-
blockers (22%), 
diuretics (60%), 
digoxin (12%). 
Not specified Not specified Not specified Not specified 
SAVE75 
N=2231. AMI 
within 3-16 
days. LVEF 
≤40% without 
overt heart 
failure or 
symptoms of 
myocardial 
ischemia. Mean 
follow-up 42 
months. 
Captopril vs. 
placebo. Beta-
blockers (36%), 
diuretics (35%), 
digitalis (26%). 
Serum 
creatinine > 221 
µmol/L (2.5 
mg/dL) 
Not specified Not specified Not specified 
EPHESUS: Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; AMI: 
acute myocardial infarction; LVEF: left ventricular ejection fraction; HF: heart failure; VALIANT: Valsartan in 
Acute Myocardial Infarction; TTE: transthoracic echocardiography; OPTIMAAL: Optimal Therapy in 
Myocardial Infarction with the Angiotensin II Antagonist Losartan; ISIS-4: The Fourth International Study of 
Infarct Survival; GISSI-3: The Third Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico 
(GISSI-2) trial; TRACE: Trandolapril Cardiac Evaluation; AIRE: Acute Infarction Ramipril Efficacy; SAVE: 
Survival and Ventricular Enlargement; ACEi: angiontensin-converting enzyme inhibitor; ARB: angiotensin II 
receptor blocker. 
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2 AIMS 
The overall aim of the thesis was to assess patient characteristics and predictors of adverse 
events in ACS including arrhythmias, cardiac arrest, and mortality. Furthermore, we sought 
to investigate the impact of potassium disorders in this setting. 
2.1 SPECIFIC AIMS 
Study I: To find possible predictors of in-hospital cardiac arrest in patients admitted with 
suspected NSTE-ACS and further to develop and validate a user-friendly risk-score for this 
purpose. 
Study II: To find possible predictors of out-of-hospital cardiac arrest early after MI within 
the time window where primary preventive ICD is not routinely recommended. 
Study III: To study the impact of potassium disorders at admission and associations to 
adverse in-hospital outcomes in patients admitted with suspected ACS. 
Study IV: To study the impact of potassium disorders at and after discharge and associations 
to adverse outcomes following MI 
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3 THESIS AT A GLANCE 
Study I II III IV 
Design Cohort study Cohort study Cohort study Cohort study 
Data source SWEDEHEART, 
MINAP 
SWEDEHEART, 
the Swedish CPR 
Registry, the 
Swedish Pacemaker 
and ICD Registry 
SWEDEHEART, 
SCREAM 
SWEDEHEART, 
SCREAM 
Time of data 
collection 
2008-2014 
(derivation cohort), 
2005-2007 
(temporal validation 
cohort), 2008-2013 
(external validation 
cohort) 
2009-2017 2006-2011 2006-2011 
Study 
population 
Cases admitted with 
suspected NSTE-
ACS 
Cases, which had 
undergone coronary 
angiography and 
were discharged 
alive after MI 
without previous 
ICD 
Patients admitted 
with suspected ACS 
Patients with MI 
discharged alive 
Numbers 
included in 
analyses 
N=242,303 
(derivation cohort); 
N=126,073 
(temporal validation 
cohort) N=276,109 
(external validation 
cohort) 
N=121,379 N=32,955 N=4861 
Follow-up time During 
hospitalization 
90 days post-
discharge or 
December 31, 2017 
During 
hospitalization 
1 year post-
discharge 
Outcomes In-hospital cardiac 
arrest 
Out-of-hospital 
cardiac arrest 
In-hospital 
mortality, cardiac 
arrest, new-onset 
AF, and 2nd- or 3rd-
degree AV-block 
Hyperkalemia, 
hypokalemia, 
mortality, 
reinfarction, heart 
failure, new-onset 
AF within 1 year 
Main statistical 
analyses 
Logistic regression Cox regression, 
Fine-Gray regression 
Logistic regression Logistic regression, 
Cox regression, 
Fine-Gray 
regression 
Conclusion A simple risk-score 
model including five 
easily accessible 
variables predicts 
the risk of in-
hospital cardiac 
arrest for patients 
admitted with 
suspected NSTE-
ACS. 
The incidence of 
OHCA at 90 days 
was low. Six clinical 
variables including 
LVEF more 
accurately predicted 
OHCA as well as 
non-OHCA death 
than an LVEF cut-
off of <40% alone. 
Hyperkalemia at 
admission is 
associated with in-
hospital mortality 
and hypokalemia is 
associated with 
cardiac arrest and 
new-onset atrial 
fibrillation in 
patients admitted 
with suspected ACS. 
Hyperkalemia and 
hypokalemia are 
common within the 
first year after MI 
discharge. 
Potassium level and 
eGFR at discharge 
strongly predict their 
occurrence, as well 
as mortality at one 
year.  
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4 METHODS 
4.1 DATA SOURCES 
All studies (Studies I-IV) were conducted using data from the Swedish Web-system for 
Enhancement and Development of Evidence-based care in Heart disease Evaluated 
According to Recommended Therapies (SWEDEHEART). In Study I, additional data from 
the Myocardial Ischaemia National Audit Project (MINAP) was used. Study II was made 
possible by merging data from SWEDEHEART, the Swedish Cardiopulmonary 
Resuscitation Registry, and the Swedish Pacemaker and ICD Registry. To carry out Studies 
III-IV, SWEDEHEART was enriched with data from the Stockholm CREAtinine 
Measurements (SCREAM) project. 
4.1.1 SWEDEHEART 
SWEDEHEART was developed in December 2009 after consolidation of the Register of 
Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS–HIA), 
the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the Swedish Heart 
Surgery Registry, and the Secondary Prevention after Heart Intensive Care Admission 
(SEPHIA)82. RIKS-HIA was launched as a regional registry in the early 1990s and developed 
into a national quality register in 1995 with the addition of SEPHIA in 2005. Swedish 
hospitals performing coronary angiography started a national angioplasty registry and a 
coronary angiography registry in the beginning of the 1990s and these were merged to form 
SCAAR in 1998. The Swedish Heart Surgery Registry was launched in 199282. 
SWEDEHEART includes patients hospitalized because of symptoms suggestive of ACS and 
patients undergoing coronary angiography/ PCI or cardiac surgery for any reason. All 
Swedish hospitals providing coronary care participate and except for secondary prevention 
(SEPHIA), the coverage is 100%. For patients admitted with suspected ACS, some 100 
variables are collected prospectively. Variables include demographics, prior medical history, 
admission logistics, medication before admission, presentation characteristics including 
clinical and electrocardiographic features, laboratory data, treatments and interventions 
during hospitalization, hospital outcomes, discharge diagnoses, and medication at discharge. 
In addition, SWEDEHEART is regularly merged with the National Cause of Death Register, 
which provides information about vital status of all Swedish citizens, the National Patient 
Registry, providing diagnoses at discharge for all hospital stays in Sweden, and with the 
Swedish Prescribed Drug Register, where all drug prescriptions in Sweden are recorded82. 
All patients are informed about their entry and follow-up in the registry and have the right to 
opt-out. A majority of variables are mandatory in order to ensure a high degree of 
completeness. To ensure data correctness, randomly assigned monitor visits to approximately 
25% of participating hospitals take place yearly, where registry-recorded data and 
information in patients’ records are compared. An agreement of over 95% has been 
reported82. 
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According to the National Board of Health and Welfare, 86.6% of acute MIs in Sweden 2015 
were captured by SWEDEHEART and there has been a slight improvement of coverage 
since 2011. According to the same report, almost 100% of PCIs and about 96% of cardiac 
surgery procedures performed in 2015 were captured by SWEDEHEART83. 
The RIKS-HIA registry forms of 2018 are shown in Figures 3-5. The present thesis is based 
on SWEDEHEART data collected from 2006 and onwards. The variables used in the 
analyses have not changed up to 2018. 
4.1.2 MINAP 
MINAP was founded in 1998. Since 2002 all acute hospitals in England and Wales are part 
of the registry84. The National Institute for Cardiovascular Outcomes Research (NICOR) 
which includes the MINAP database (Ref: NIGB: ECC 1-06 (d)/2011) has support under 
section 251 of the National Health Service Act 2006 to use patient information for medical 
research without consent. Hospitals are requested to register all patients admitted with ACS. 
However, under-reporting has been observed, in particular for NSTEMI, with over 40% of 
cases estimated to be missing. Over 100 variables are collected including demographics, prior 
medical history, prior drug treatment, admission method, clinical features and investigations, 
drug treatment in hospital, interventional treatments, hospital outcome, complications, 
discharge diagnosis, and discharge treatment. Additionally, MINAP is regularly linked to the 
Office for National Statistic’s registry to assess patients’ vital status. Participating hospitals 
are recurrently monitored regarding validation and completeness of entered data84. 
4.1.3 The Swedish Cardiopulmonary Resuscitation Registry 
The Swedish Cardiopulmonary Resuscitation Registry was started in 1990. Registration 
coverage has increased considerably over time and is now almost 100% as all Swedish 
emergency medical service (EMS) stations participate. All patients with out-of-hospital 
cardiac arrest (OHCA) where attempted resuscitation by EMS personnel and/or a bystander 
has been performed are eligible for inclusion except for cases where cardiopulmonary 
resuscitation (CPR) was initiated by a bystander but not continued by EMS personnel 
because of definite signs of death. Registry reporting is made in two steps. First, EMS 
personnel register baseline data including time and date of OHCA, treatment, initial rhythm, 
and outcome. If applicable, a local CPR coordinator with access to in-hospital medical 
records, registers in-hospital treatments, outcomes, and diagnoses. Cardiac arrest survivors 
are informed about their entry in the registry and may choose to opt out. Non-survivors are 
included without consent85. 
4.1.4 The Swedish Pacemaker and ICD Registry 
The Swedish Pacemaker Registry was started in 1989. Since 2004 data on ICD implants are 
also reported. The registry covers almost 100% of the total pacemaker and ICD implanting 
activity in Sweden with 44 centers reporting data. Informed consent is required for data entry 
by the ethics committee of individual participating hospitals. Reported variables include 
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patient demographics, clinical indication for implantation, etiology, surgical procedural data, 
perioperative and postoperative complications, number of implants or replacements per 
center, and technical information on generators and leads86. 
4.1.5 SCREAM 
SCREAM is a repository of laboratory data of residents of the Stockholm County, who had a 
valid personal identifying number, were at least 18 years old, and underwent creatinine 
testing between 2006 and 201187. The cohort comprises data from 1,118,507 individuals. 
Laboratory data was provided from Aleris, Unilabs, and Karolinska University Hospital 
Laboratory, the three laboratories performing nearly all laboratory tests within the Stockholm 
region. Inter- and intra-laboratory variation was considered to be negligible as laboratory 
quality and harmonization is regularly monitored by Equalis, a national provider of external 
quality assessment for clinical laboratory investigations in Sweden. All creatinine tests 
analyzed within the time period were included in addition to other routine laboratory 
measurements, such as electrolytes, glucose, and hemoglobin. Each provided test included 
date, method used, and units of measurement. The SCREAM dataset was further enriched 
with data from the regional administrative health data register (Vårdanalysdatabasen, VAL; 
Stockholm Regional Healthcare Data Warehouse) including demographics and information 
(date, center and medical department, clinical diagnoses, and therapeutic procedures) on all 
healthcare visits in primary and secondary care, as well as hospitalizations. Additionally, the 
SCREAM dataset was linked to the Swedish Population Registry, the Swedish Prescribed 
Drug Registry, the Longitudinal Integration Database for Health Insurance and Labour 
Market Studies (LISA by Swedish acronym), and the Swedish Renal Registry. The SCREAM 
project is approved by the Ethical Committee of Stockholm87. 
4.2 DEFINITIONS 
All variables were defined according to each respective registry. In SWEDEHEART, in-
hospital cardiac arrest is defined as cardiac arrest requiring defibrillation and/or CPR. This 
variable is categorized as “VT/VF”, “other causes of cardiac arrest”, or “no cardiac arrest”. In 
order to overcome possible misclassification of type of cardiac arrest, we used a 
dichotomized variable defined as in-hospital cardiac arrest “yes” or “no” in Studies I and III. 
In Studies III-IV, hypokalemia was defined as plasma potassium <3.5 mmol/L. 
Hyperkalemia was defined as plasma potassium ≥5.0 mmol/L in Study III and as plasma 
potassium >5.0 mmol/L in Study IV. 
4.3 STUDY POPULATION 
4.3.1 Study I 
A derivation cohort was developed using data from SWEDEHEART between January 1, 
2008 and December 31, 2014. All registered patients admitted with symptoms suggestive of 
NSTE-ACS were eligible for entry. Patients were eligible for entry more than once if they 
were admitted multiple times during the study period. Exclusion criteria included cardiac 
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arrest before admission or missing data on cardiac arrest before admission or during 
hospitalization. The same inclusion and exclusion criteria were applied for selection of a 
temporal and an external validation cohort. The temporal validation cohort comprised 
patients registered in SWEDEHEART between January 1, 2005 and December 31, 2007. The 
external validation cohort included patients registered in MINAP between January 1, 2008 
and December 31, 2013. 
4.3.2 Study II 
All patients registered in SWEDEHEART, who were discharged alive after an acute MI 
between January 1, 2009 and December 31, 2017, and had undergone in-hospital coronary 
angiography were eligible for entry. Patients, who had an ICD implanted prior to admission, 
during the hospital course, or during follow-up, as registered in the Swedish Pacemaker and 
ICD Registry, were excluded. Patients could enter the study multiple times if a new MI 
admission was more than 90 days apart from the last preceding MI discharge date. 
4.3.3 Study III 
All consecutive patients admitted with symptoms suggestive of ACS and registered in 
SWEDEHEART and SCREAM between January 1, 2006 and July 1, 2011 were eligible for 
entry. Patients who did not have a potassium test available at admission or had cardiac arrest 
before admission were excluded. 
4.3.4 Study IV 
All consecutive patients discharged alive after an acute MI and registered in SWEDEHEART 
and SCREAM between January 1, 2006 and December 31, 2010 were eligible for entry. 
Patients who did not have a potassium test and/or a creatinine test available at discharge date 
(± one day) were excluded as were patients undergoing hemodialysis or peritoneal dialysis 
during index hospitalization. 
4.4 STATISTICS 
Categorical data are expressed as number (n) and proportion (%) of patients. Continuous data 
are presented as median with interquartile range (IQR) or mean with standard deviations 
(SD). In all analyses, a p-value of <0.05 was considered statistically significant. Statistical 
analyses were performed with Stata version 13.1 (Study I), Stata version 15.1 (Study II), and 
Stata version 14.0 (Studies III-IV) (Stata Corporation, College station, Texas, USA). In 
Study I, additional statistics were performed using R version 3.1.0 (R Foundation for 
Statistical Computing, Vienna, Austria). 
4.4.1 Study I 
Multivariable regression models were used to assess associations between 26 candidate 
baseline variables and in-hospital cardiac arrest. Using backward selection, variables were 
selected for inclusion in a risk-score model, which was developed according to the points 
system described by Sullivan et al.88 Internal, temporal, and external validations including an 
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additional model adjusting for underlying risk were assessed by graphically determining the 
calibration curves and calculating the area under the receiver operating characteristic (ROC) 
curves. Missing data was imputed using multiple imputation by chained equations (MICE)89. 
For the purpose of sensitivity analyses, risk-score model performance was assessed using 
complete-case data only as well as using first-time admissions only, i.e. unique patients. 
4.4.2 Study II 
Cox proportional hazard models were used to assess the association between 24 candidate 
variables and the occurrence of OHCA within 90 days after discharge. Patients who died 
during follow-up without having OHCA registered were censored. A prediction model was 
developed using backward selection. In the final model, interaction terms were tested for all 
variables. Furthermore, we constructed a simple risk-score model, where the included 
variables were assigned points approximately corresponding to the hazard ratios. As a 
sensitivity analysis, all candidate variables were tested and a predictive model was developed 
using Fine-Gray models with mortality in the non-OHCA group as the competing event. Only 
complete-case analyses were used for this study. 
4.4.3 Study III 
We assessed the associations between admission plasma potassium categories (reference 3.5-
<4.0 mmol/L) and in-hospital outcomes: mortality, cardiac arrest, new-onset atrial 
fibrillation/ flutter, and second- or third-degree AV block. Multivariable adjustment with 
logistic regression was applied using three models, adjusting for an increasing number of 
covariates (24 in total). Associations between exposure (plasma potassium per mmol/L) and 
outcomes were also graphically modeled using cubic spline logistic regression, adjusting for 
all covariates. Interaction terms were tested for a subset of covariates. Missing data was 
imputed using MICE. 
4.4.4 Study IV 
The odds of hyperkalemia or hypokalemia at discharge were assessed using multivariable 
logistics regression and adjusting for 21 covariates. Multivariable Cox proportional hazard 
models were used to assess associations between discharge plasma potassium categories 
(reference 4.0-<4.5 mmol/L) and hyperkalemia or hypokalemia within one year (with a 
blanking period of two weeks post-discharge) as well as mortality within one year. Fine-Gray 
regression models were used to assess associations between discharge plasma potassium 
categories and hospitalization due to reinfarction, hospitalization due to heart failure, or new-
onset atrial fibrillation/ flutter within one year, where death was the competing event. In the 
above mentioned time-dependent regression analyses, 19 covariates were included. 
Associations between discharge plasma potassium and outcomes were also assessed using 
restricted cubic splines. There were no missing data on variables used in the regression 
models. 
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4.5 ETHICAL CONSIDERATIONS 
All studies were approved by the regional ethical review board in Stockholm and conducted 
in accordance with the declaration of Helsinki90. Data were only analyzed on a group level 
and the results cannot be linked back to an individual patient 
Figure 3A. RIKS-HIA registry form. Data collected on admission. 
  
SWEDEHEART – 2018 PatientID: 
START – RIKSHIA (1/2)              ( * = obligatorisk) 
Överflyttad patient* 
Överflyttad från 0 Nej 1 Omdirigerad 
ambulans 
2 Annat 
sjukhus 
3 Annan vårdenhet 
inom sjukhuset 
4 Ej 
registrerande 
enhet 
Ange sjukhus 
/enhet (om 1-4) 
 
Beslutsgrundande EKG och ankomststatus* 
EKG rytm 1 Sinus 2 Förmaksflimmer/-fladder 8 Övrigt  
EKG QRS 1 Normalt 2 Pacemaker 3 Vänster-
grenblock 
4 Patol Q-
våg 
5 Höger-
grenblock 
8 Övrigt  
Vänstergrenblock 0 Tidigare 
känt 
1 Ej tidigare känt 
EKG STT 1 Normalt 2 ST-höjning 3 ST-sänkning 4 Patologisk T-våg 8 Övrigt  
Hjärtfrekvens  /min      
Blodtryck 
Syst/diast 
 /      
Lungrassel 0 Nej 1 Basala 
rassel 
2 Mer än halva lungorna 
 
3 Lungödem 
Cardiogen chock 
vid ankomst 
0 Nej 1 Ja      
Prehospitala uppgifter* 
Intagningsorsak 1 Bröstsmärta 2 Dyspné 3 Cirkulationsstillestånd 8 Övrigt 
Symtomdebut Datum Kl 
Ambulans 0 Nej 1 Ja, till Akuten 2 Ja, till HIA/PCI-lab 
Prehospitalt EKG 
Tidpunkt 
Datum Kl 
HLR före sjukhus 0 Nej 1 Ja 
Prehospital 
trombolys 
0 Nej 1 Ja 
Preh trombolys 
läkemedel 
 3 Rapilysin 4 Metalyse 
Preh trombolys 
tidpunkt 
Datum Kl 
Ankomstuppgifter* 
Ankomst till akuten Datum  Kl 
Avresa till PCI-sjukhus 0 Nej 1 Ja 
HIA/AVD/PCI-lab Datum Kl 
Klinisk bakgrund* 
Längd _____   cm 
Vikt _____   kg 
Sysselsättning 1 Arbete 2 Sjukskrivning 
/sjukersättning 
3 Arbetslöshet 4 Ålderspensionär 5 Studerar/Övrigt 
Riskfaktorer 
Rökning* 0 Aldrig rökare 1 Ex rökare > 1 mån 2 Rökare 
Snusning* 0 Aldrig varit snusare 1 Ex snusare > 1 mån 2 Snusare 
Skörhet 1 Mycket vital 2 Vital 3 Klarar sig bra 4 Sårbar 5 Lindrigt skör 
 6 Måttligt skör 7 Allvarligt skör 8 Mycket allvarligt skör 9 Terminalt sjuk 
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Figure 3B. RIKS-HIA registry form. Data collected on admission (continued). 
  
SWEDEHEART – 2018 PatientID: 
START – RIKSHIA (2/2) 
Tidigare hjärtsjukdom* 
Tidigare hjärt-
infarkt 
0 Nej 1 Ja     
Känd nedsatt 
vänsterkammar-
funktion 
0 Nej  2 Ja, lätt nedsatt 
(40-49%) 
3 Ja, måttligt 
nedsatt (30-
39%) 
4 Ja, kraftigt 
nedsatt 
(<30%) 
5 Ja, men 
okänd grad 
Tidigare PCI 0 Nej 1 Ja     
Tidigare hjärt-
kirurgi (avser ej 
pacemaker) 
0 Nej 1 CABG 2 Annan hjärtkirurgi 
Tidigare sjukdomar* 
Diabetes 0 Nej 1 Ja 
Hypertoni 0 Nej 1 Ja 
Tidigare stroke (ej 
TIA) 
0 Nej 1 Ja 
Medicin vid ankomsten* 
ACE-hämmare 0 Nej 1 Ja      
A2-blockerare 0 Nej 1 Ja 2 ARB + 
Neprilysin 
    
Antikoagulantia 0 Nej 1 Waran  3 Dabigatran 
(Pradaxa) 
4 Rivaraoxaban 
(Xarelto) 
5 Apixaban 
(Eliquis) 
 
ASA 0 Nej 1 Ja      
Övriga trombocyt-
hämmare 
0 Nej 1 Clopidogrel 
(Plavix) 
2 Tiklopidin 
(Ticlid) 
3 Prasugrel 
(Efient) 
4 Ticagrelor 
(Brilique) 
8 Övrigt  
Betablockerare 0 Nej 1 Ja      
Ca-hämmare 0 Nej 1 Ja      
Diabetesbe-
handling insulin 
0 Nej 1 Insulin      
Diabetesbehand-
ling per oral 
0 Nej 1 Tablettbehandlad      
Digitalis 0 Nej 1 Ja      
Diuretika 0 Nej 1 Ja      
Aldosteron-
blockad 
0 Nej 1 Spironolakton 
(Aldactone) 
2 Eplerenon 
(Inspra) 
  8 Övrigt  
Statiner 0 Nej 1 Ja      
Ezetimibe 
(Ezetrol) 
0 Nej 1 Ja      
Övriga lipid-
sänkare 
0 Nej 1 Ja Om Ja:    
  2 Fibrater 3 PCSK9-
antikroppar 
4 Lipoproteinaferes 8 Övrigt 
Nitroglycerin 
långverkande 
0 Nej 1 Ja      
Kommentarer 
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Figure 4. RIKS-HIA registry form. Data collected from the hospital course.  
  
SWEDEHEART – 2018 PatientID: 
VÅRD – RIKSHIA                ( * = obligatorisk) 
Ankomst HIA/Avd/PCI-lab* Datum Kl 
Revaskularisering* 
Reperfusionsbehandling 0 Nej 1 Trombolys 2 Primär PCI 3 Akut CABG 4 Akut cor.ai utan åtgärd 
Trombolys 0 Nej 1 Streptokinas 2 Actilyse 3 Rapilysin 4 Metalyse 
Trombolys kontraindikation 0 Nej 1 Ja    
Trombolys tidpunkt Datum  Kl   
Reperfusionsgrundande EKG 
= Prehospitalta EKG 
0 Nej 1 Ja    
Reperfusiongrundande EKG 
Tid 
Datum  Kl   
Medicinering* 
iv/sc Antikoagulantia 0 Nej 1 iv Heparin 2 sc Fragmin/Klexane 3 Arixtra 
iv Betablockerare 0 Nej 1 Ja   
iv Diuretika 0 Nej 1 Ja   
iv Inotropa 0 Nej 1 Ja   
iv Nitroglycering 0 Nej 1 Ja   
Utredningar och behandlingar* 
Typ av stresstest 0 Ej utfört 1 Myocardscint 2 Stress EKO 3 Arbetsprov  
Resultat av stresstest  1 Normalt 2 Patologiskt 3 Ej bedömbart  
Vänsterkammar-funktion 
mätt 
 1 Ekokardiografi 2 LV-angio 3 Annan metod  
Vänsterkammarfunktion 
(LVEF) 
 1 Normalt (≥50%) 2 Lätt nedsatt 
(40-49%) 
3 Måttligt 
nedsatt (30-
39%) 
4 Kraftigt nedsatt 
(<30%) 
CABG 0 Nej 1 Ja, akut CABG 2 Ja, under vårdtillfället 3 Planerad efter utskrivning 
PM/ICD 0 Nej 1 PM permanent 2 ICD 4 CRT 5 ICD+CRT 
CPAP 0 Nej 1 Ja    
Laboratorieuppgifter                                                              OBS! Ankomstprover: Hb, CRP, Krea och P-Glucos 
Infarktmarkör 0 Ej utfört 1 Trop T (µg) 2 Trop I 3 CKMB 5 HS Trop T (ng) 6 HS Trop I (ng) 
Maxvärde infarktmarkör   
Kolesterol  Triglycerider  HDL  ApoB  ApoA1  
LDL direktmätt:   
P-Glucos  HbA1c  Prov 2 Prov 3 
Kreatinin*  Dat Kl Dat Kl Dat Kl 
CRP  Dat Kl Dat Kl Dat Kl 
Hb  Dat Kl Dat Kl Dat Kl 
Komplikationer 
Reinfarkt under vårdtillfället* 0 Nej 1 Ja   
Blödning under vårdtillfället* 0 Nej 1 Dödlig 2 Cerebral 3 Krävande op/transfusion 
HLR/Defibrillering under vtf* 0 Nej 1 VT/VF  8 Övrigt 
Cardiogen chock* 0 Nej 1 Ja   
AV-block* 0 Nej/AV-I 1 AV-II-III   
Nytt förmaksflimmer* 0 Nej 1 Ja   
Mekanisk komplikation 0 Nej 1 Fri väggruptur 2 VSD 3 MI (Akut allvarlig MI) 
Överföring utskrivning* 
Överförs till vårdenhet/sjukhus  
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Figure 5. RIKS-HIA registry form. Data collected at discharge. 
  
SWEDEHEART – 2018 PatientID: 
SLUT – RIKSHIA               ( * = obligatorisk) 
Ankomst HIA/Avd/PCI* Datum 
Avliden* 
Avliden 0 Nej 1 Ja 
Medicinering* 
ACE-hämmare 0 Nej 1 Ja     
A2-blockerare 0 Nej 1 Ja 2 ARB + Neprilysin 
Antikoagulantia 0 Nej 1 Waran 3 Dabigatran 
(Pradaxa) 
4 Rivaroxaban 
(Xarelto) 
5 Apixaban 
(Eliquis) 
8 Annat 
ASA 0 Nej 1 Ja     
Planerad behandlingstid  1 1 mån 2 3 mån 3 6 mån 6 >=12 mån  
Övriga trombocythämmare 0 Nej 1 Clopidogrel 
(Plavix) 
2 Tiklopidin 
(Ticlid) 
3 Prasugrel 
(Efient) 
4 Ticagrelor 
(Brilique) 
8 Övrigt 
Planerad behandlingstid  1 1 mån 2 3 mån 3 6 mån 6 >=12 mån 5 tillsvidare 
Betablockerare 0 Nej 1 Ja     
Ca-hämmare 0 Nej 1 Ja     
Diabetesbeh insulin 0 Nej 1 Insulin     
Diabetsbeh per oral 0 Nej 1 Tablettbeh     
Digitalis 0 Nej 1 Ja     
Diuretika 0 Nej 1 Ja     
Aldosteronblockad 0 Nej 1 Spironolakton 
(Aldacton) 
2 Eplerenon 
(Inspra) 
  8 Övrigt 
Statiner 0 Nej 1 Ja     
Ezetimibre (Ezetrol) 0 Nej 1 Ja     
Övriga lipidsänkare 0 Nej 1 Ja    Om Ja: 2 Fibrater 3 PCSK9-
antikroppar 
4 Lipoprotein-
aferes 
8 Övrigt 
Nitroglycering långv 0 Nej 1 Ja     
EKG* 
EKG-rytm 1 Sinus 2 Förmaksflimmer/-fladder 8 Övrigt 
Diagnos* 
Infarkttyp 0 Ej infarkt 1 STEMI 2 NSTEMI 
Subklass. av hjärtinfarkt  1 Typ-1 2 Typ-2 3 Typ-3 4 Typ-4a 5 Typ-4b 6 Typ-5 
Diagnos 1 Diagnos 3 Diagnos 5 
Diagnos 2 Diagnos 4 Diagnos 6 
Utskrivning* 
Utskrivningsdatum  
Planerad koronarangio efter utskrivning  0 Nej 1 Ja 
Planerad PCI efter utskrivning 0 Nej 1 Ja 
Planerad CABG efter utskrivning 0 Nej 1 Ja 
Uppföljning 0 Nej 1 Kardiologi/Medicin 2 VC 3 Annan 
Uppföljande sjukhus/enhet 
 
Predictors of Arrhythmias, Cardiac Arrest, and Mortality in Acute Coronary Syndrome 
 33 
5 RESULTS 
5.1 STUDY I 
In the derivation cohort (n=242,303), 2077 (0.9%) cases of in-hospital cardiac arrest were 
registered. Restricted to patients with a final diagnosis of NSTE-ACS (42%), in-hospital 
cardiac arrest accounted for 1365 (1.3%) cases. The corresponding number among patients 
with a non-ACS diagnosis was 712 (0.5%). Figure 6 depicts the incidence of in-hospital 
cardiac arrest by year and final diagnosis (NSTE-ACS and non-ACS) for the derivation 
cohort, as well as for the temporal validation and external validation cohorts. 
Overall in the derivation cohort, patients with in-hospital cardiac arrest tended to be older and 
have a higher burden of comorbidities. They were also more prone to have 
electrocardiographic ST-T-abnormalities, lower systolic blood pressure and eGFR, higher 
heart rate, Killip class and blood glucose level. 
A points-based risk score with a maximal sum of seven points was developed. The included 
variables were: age ≥60 years (1 point), ST-T abnormalities (2 points), Killip Class >1 (1 
point), heart rate <50 or ≥100 bpm (1 point), and systolic blood pressure <100 mmHg (2 
points). Estimated risk of in-hospital cardiac arrest by sum of points in the risk score ranged 
from 0.18% to 11.94%.  
Figure 6. Incidence of in-hospital cardiac arrest by year and final diagnosis in 
SWEDEHEART and MINAP. 
Internal validation showed good discrimination with a c-statistic of 0.72 (95% CI, 0.71–0.73). 
The calibration plot demonstrated reasonable agreement but there was a tendency towards 
overestimation of risk with a higher sum of score points (Figure 7A). The risk score 
performed similarly in the temporal validation cohort (n=126,073) with respect to 
discrimination (c-statistic 0.74 [95% CI, 0.73–0.76]) and calibration but instead there was a 
tendency towards overestimation of risk with a higher sum of score points (Figure 7B). 
In the external validation cohort (n=276,109) from MINAP there were 6388 (2.3%) cases of 
in-hospital cardiac arrest. The incidence was equal in patients with NSTE-ACS (87%) and 
patients with a non-ACS diagnosis. Baseline characteristic differences between cardiac arrest 
0,00	
0,50	
1,00	
1,50	
2,00	
2,50	
3,00	
3,50	
2005	 2006	 2007	 2008	 2009	 2010	 2011	 2012	 2013	 2014	
In
-h
os
pi
ta
l	C
ar
di
ac
	A
rr
es
t,	
%
	
Years	
No	ACS	-	SWEDEHEART	temporal	
validaCon	cohort		
NSTE-ACS	-	SWEDEHEART	temporal	
validaCon	cohort		
No	ACS	-	SWEDEHEART	derivaCon	
cohort	
NSTE-ACS-	SWEDEHEART	derivaCon	
cohort	
No	ACS	-	MINAP	validaCon	cohort	
NSTE-ACS	-	MINAP	validaCon	cohort	
Jonas Faxén 
34 
and non-cardiac arrest cases were comparable to the derivation cohort. The external 
validation demonstrated moderate discrimination (c-statistic 0.65 [95% CI, 0.65–0.66]). The 
calibration plot showed a general underestimation of risk (Figure 7C). A separate model 
adjusting for underlying risk demonstrated good discrimination in the lower range of sum of 
points but a general overestimation of risk with an increasing sum of points. 
Figure 7. Calibration plot for the SWEDEHEART derivation cohort 2008-2014 (A), the 
SWEDEHEART  temporal validation cohort 2005-2007 (B), and the MINAP validation 
cohort 2008-2013 (C). 
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5.2 STUDY II 
Among the 121,379 include cases in the cohort, there were 349 (0.29%) OHCA recorded in 
the Swedish Cardiopulmonary Resuscitation Registry within 90 days after discharge. Among 
non-OHCA cases, 2194 (1.8%) died during the follow-up period (Figure 8). 
 
Figure 8. Frequencies of OHCA and non-OHCA death within 90 days after discharge. 
Compared to non-OHCA cases, patients with OHCA were older, more likely to be male, have 
a history of diabetes and heart failure, and a lower eGFR on admission. Patients with OHCA 
were also more likely to have STEMI (as opposed no NSTEMI), multivessel and/or left main 
coronary artery disease, a more complicated hospital course, and a lower LVEF assessed 
during hospitalization. 
Compared to patients with OHCA, those with non-OHCA death were more likely to be 
female, have three-vessel and/or left main coronary artery disease, and a lower eGFR and 
hemoglobin on admission. 
Eight variables were independently associated with OHCA in multivariate Cox analyses. The 
two variables diabetes and STEMI had the weakest associations and were excluded from the 
final prediction model, which comprised six variables: male sex, age ≥60 years, eGFR <30 
mL/min per 1.73 m2, Killip class ≥II, new-onset atrial fibrillation/flutter, and LVEF 
categorized as ≥50% (reference), 40-49%, 30-39%, and <30% (Table 3). In the sensitivity 
analysis, using Fine-Gray models with death in the non-OHCA groups as competing risk, the 
same variables were independently associated with OHCA. 
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Table 3. Variables associated with OHCA within 90 days after MI discharge in multivariate 
Cox models and points assigned for stratification.  
Variable HR (95% CI) P-value Points 
Male sex 1.75 (1.31-2.33) <0.001 1 
Age ≥60 years 1.56 (1.09-2.25) 0.016 1 
eGFR <30 mL/min per 1.73 m2  2.42 (1.57-3.72) <0.001 2 
Killip class ≥II 2.20 (1.64-2.95) <0.001 2 
New-onset atrial fibrillation/flutter 1.67 (1.13-2.47) 0.01 1 
LVEF 40-49% (ref ≥50%) 2.74 (2.00-3.76) <0.001 2 
LVEF 30-39% (ref ≥50%) 4.21 (3.04-5.83) <0.001 3 
LVEF <30% (ref ≥50%) 6.24 (4.25-9.17) <0.001 4 
HR: hazard ratio; CI: confidence interval; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction. 
The six variables were assigned points approximately corresponding to their hazard ratios 
(HRs) (Table 3). For further simplicity, sum of points were grouped into four categories, 
where the incidence of OHCA ranged from 0.11% to 2.2% and non-OHCA death from 
0.65% to 11.5% Stratified by LVEF <40% alone, the incidence of OHCA was 0.20% and 
0.76% and for non-OHCA death 1.1% and 4.9% (Figure 9A-D). 
 
Figure 9. Kaplan-Meier estimates of the rate of OHCA (A, B) and non-OHCA death (C, D) 
stratified by sum of points and an LVEF cut-off of <40% respectively, 
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5.3 STUDY III 
The cohort comprised 32,955 patients, of whom 44.6% had confirmed ACS and NSTE-ACS 
accounted for 70.3%. Mean admission plasma potassium was 4.0±0.5 mmol/L. The 
proportion of patients within each potassium stratum were: <3.0 mmol/L (1%), 3.0-<3.5 
mmol/L (9%), 3.5-<4.0 mmol/L (39%), 4.0-<4.5 mmol/L (38%), 4.5-<5.0 mmol/L (10%), 
5.0-<5.5 mmol/L (2%), and ≥5.5 mmol/L (1%). Overall, patients with higher potassium 
levels tended to be older, have more comorbidities, and a lower eGFR.  
Figure 10 illustrates crude proportions of outcomes according to potassium strata stratified 
by final diagnosis (STEMI, NSTE-ACS, and non-ACS). During hospitalization, 886 (2.7%) 
patients died. A U-shaped association between admission plasma potassium and in-hospital 
mortality was observed. This association remained after adjusting for age, sex, and 
additionally eGFR strata, comorbidities, main diagnosis, and medication on admission. 
However, after further adjustment for presentation characteristics, only plasma potassium 
≥5.0 mmol/L was significantly associated with in-hospital mortality (Table 4). 
Figure 10. Proportions of outcomes by plasma potassium categories and final diagnosis. 
There were 494 (1.5%) cases of in-hospital cardiac arrest registered. Also here, a U-shaped 
association to admission plasma potassium was observed. This association remained after 
adjusting for sex, age, eGFR strata, comorbidities, main diagnosis, and medication on 
admission. After adjusting for all covariates including presentation characteristics, only 
plasma potassium <3.5 mmol/L was significantly associated with in-hospital cardiac arrest 
(Table 4). 
New-onset atrial fibrillation/flutter was observed in 804 (2.4%) patients during 
hospitalization. Only plasma potassium <3.0 mmol/L was significantly associated with new-
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onset atrial fibrillation/flutter after adjusting for all covariates (Table 4). A total of 361 
(1.1%) patients experienced in-hospital second- or third-degree AV-block. After adjusting for 
age, sex, gender, eGFR strata, comorbidities, main diagnosis, and medication on admission, 
plasma potassium ≥5.5 mmol/L was significantly associated with second- or third-degree 
AV-block. This association did not remain after additional adjustment for presentation 
characteristics (Table 4). 
No significant interactions were found between admission plasma potassium strata and final 
diagnosis (STEMI, NSTE-ACS or non-ACS), eGFR strata, sex, presentation characteristics, 
or medication. 
Table 4. Odds ratios (OR) and 95% confidence intervals (CI) for in-hospital outcomes by 
plasma potassium level on admission.
	 	 	 	 Model	1	
Adjusted	for	age,	
sex	
Model	2*	
	
Model	3**	
	
Plasma	potassium	level	on	
admission,	mmol/L	
No.	Of	
patients	
No.	Of		
events	
Event	
rate,	
%	
OR	 (95	%	CI)	 OR	 (95	%	CI)	 OR	 (95	%	CI)	
In-hospital	mortality	
<3.0	 335	 14	 4.18	 2.25**	 [1.28,3.96]	 1.98*	 [1.11,3.52]	 1.60	 [0.89,2.88]	
3.0-<3.5	 2,908	 75	 2.58	 1.41*	 [1.07,1.84]	 1.29	 [0.98,1.69]	 1.15	 [0.86,1.52]	
3.5-<4.0	 12,711	 225	 1.77	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	
4.0-<4.5	 12,630	 263	 2.08	 0.95	 [0.79,1.14]	 0.89	 [0.74,1.07]	 0.91	 [0.75,1.10]	
4.5-<5.0	 3,276	 165	 5.04	 1.74***	 [1.41,2.15]	 1.30*	 [1.04,1.63]	 1.22	 [0.97,1.54]	
5.0-<5.5	 759	 80	 10.54	 3.49***	 [2.65,4.60]	 1.98***	 [1.47,2.67]	 1.83***	 [1.34,2.49]	
>=5.5	 336	 64	 19.05	 6.29***	 [4.58,8.64]	 3.05***	 [2.16,4.32]	 2.27***	 [1.57,3.27]	
In-hospital	cardiac	arrest	
<3.0	 335	 16	 4.78	 4.27***	 [2.52,7.25]	 3.21***	 [1.86,5.54]	 2.72***	 [1.56,4.74]	
3.0-<3.5	 2,908	 71	 2.44	 2.10***	 [1.58,2.80]	 1.83***	 [1.37,2.44]	 1.63**	 [1.21,2.19]	
3.5-<4.0	 12,711	 152	 1.2	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	
4.0-<4.5	 12,630	 142	 1.12	 0.84	 [0.67,1.06]	 0.83	 [0.66,1.05]	 0.85	 [0.67,1.08]	
4.5-<5.0	 3,276	 73	 2.23	 1.48**	 [1.11,1.98]	 1.20	 [0.89,1.61]	 1.11	 [0.82,1.50]	
5.0-<5.5	 759	 24	 3.16	 2.03**	 [1.30,3.16]	 1.27	 [0.80,2.03]	 1.20	 [0.75,1.92]	
>=5.5	 336	 16	 4.76	 2.93***	 [1.72,5.00]	 1.87*	 [1.05,3.33]	 1.41	 [0.78,2.55]	
New-onset	atrial	fibrillation	(n=29,307)	
<3.0	 286	 10	 3.50	 2.66**	 [1.38,5.11]	 2.22*	 [1.14,4.32]	 1.93*	 [1.00,3.76]	
3.0-<3.5	 2,576	 41	 1.59	 1.18	 [0.83,1.67]	 1.07	 [0.75,1.52]	 0.98	 [0.69,1.40]	
3.5-<4.0	 11,592	 156	 1.35	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	
4.0-<4.5	 11,237	 172	 1.53	 0.98	 [0.79,1.22]	 0.96	 [0.76,1.19]	 0.96	 [0.77,1.21]	
4.5-<5.0	 2,738	 74	 2.70	 1.43*	 [1.07,1.90]	 1.23	 [0.91,1.65]	 1.18	 [0.87,1.58]	
5.0-<5.5	 601	 19	 3.16	 1.54	 [0.95,2.52]	 1.15	 [0.69,1.91]	 1.05	 [0.63,1.75]	
>=5.5	 277	 9	 3.25	 1.47	 [0.74,2.93]	 1.14	 [0.56,2.36]	 0.88	 [0.42,1.83]	
2nd	/3rd	degree	atrioventricular	block	
<3.0	 335	 3	 0.9	 1.09	 [0.34,3.45]	 0.89	 [0.28,2.84]	 0.70	 [0.22,2.29]	
3.0-<3.5	 2,908	 26	 0.89	 1.07	 [0.70,1.65]	 0.96	 [0.62,1.48]	 0.85	 [0.55,1.31]	
3.5-<4.0	 12,711	 108	 0.85	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	
4.0-<4.5	 12,630	 131	 1.04	 1.05	 [0.81,1.36]	 1.05	 [0.81,1.36]	 1.03	 [0.80,1.35]	
4.5-<5.0	 3,276	 60	 1.83	 1.55**	 [1.12,2.14]	 1.37	 [0.98,1.92]	 1.20	 [0.86,1.69]	
5.0-<5.5	 759	 18	 2.37	 1.88*	 [1.13,3.14]	 1.37	 [0.80,2.32]	 1.18	 [0.70,2.04]	
≥5.5	 336	 15	 4.46	 3.35***	 [1.91,5.86]	 2.44**	 [1.344.48]	 1.54	 [0.82,2.90]		
 *Model 2 adjusted for age, sex, eGFR strata (≥60, 30-59, <30), comorbidities (hypertension, diabetes, prior myocardial infarction, history of 
heart failure, prior stroke, peripheral vascular disease), main diagnosis (non-ACS, NSTE-ACS, STEMI), and medication on admission 
(ACEI/ARB, DAPT, beta-blocker, calcium channel blocker, statins, diuretics, aldosterone antagonist and nitrates).  
**Model 3 further adjusted for systolic blood pressure, heart rate category (<50 or >100 bpm), presenting chest pain, Killip≥2, ECG rhythm 
(sinus rhythm, atrial flutter/ fibrillation, other), ECG ST-T changes (no, ST elevation, ST depression, T-wave changes, or other).  
Abbreviations: OR, Odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; ACS, acute coronary syndrome; NSTE, 
non-ST elevation; STEMI, ST-elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; DAPT, dual antiplatelet therapy; bpm, beats per minute; ECG, electrocardiography; * p<0.05 ** p<0.01 ***p<0.001 
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5.4 STUDY IV 
There were 4861 patients with confirmed acute MI included in the cohort. NSTEMI 
accounted for 70% of all MI cases. Mean plasma potassium at discharge was 4.0±0.4 
mmol/L. While most patients were discharged with plasma potassium within normal range, 
8.1% had potassium <3.5 mmol/L and 1.5% had potassium >5.0 mmol/L. A higher burden of 
comorbidities and a lower eGFR were more common among patients with elevated potassium 
at discharge. After multivariable adjustment, a strong association between lower eGFR strata 
and hyperkalemia (>5.0 mmol/L) at discharge was observed. Hyperkalemia was also 
associated with a prior diagnosis of diabetes and prior use of ACEi. Hypokalemia (<3.5 
mmol/L) at discharge was significantly associated with older age, female sex, a prior 
diagnosis of hypertension, treatment with intravenous diuretics during hospitalization, and 
non-invasive treatment of MI during the hospital course (Table 5). 
Table 5. Cross-sectional logistic regression analyses identifying factors associated with 
hypokalemia and hyperkalemia at discharge. 
	 Discharge	Hypokalemia	
K<3.5	mmol/L	
Discharge	Hyperkalemia	
K>5.0	mmol/L		 OR	 95%CI	 OR	 95%CI	
eGFR	strata,	ml/min/1.73m2	90+	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	60-89	 0.96	 [0.68,1.36]	 2.13	 [0.59,7.72]	45-59	 0.82	 [0.54,1.26]	 4.68*	 [1.21,18.06]	30-44	 0.62	 [0.39,1.01]	 9.95***	 [2.58,38.34]	<30	 0.44**	 [0.25,0.77]	 17.08***	 [4.39,66.55]	
Demographics	 	 	 	 	Age,	per	10	years	 1.18**	 [1.04,1.33]	 0.94	 [0.72,1.22]	Male	sex	 0.78*	 [0.63,0.98]	 0.89	 [0.55,1.45]	
Comorbid	history	Diabetes	mellitus	 0.95	 [0.74,1.21]	 1.74*	 [1.06,2.86]	Hypertension	 1.43**	 [1.12,1.83]	 1.20	 [0.71,2.03]	Myocardial	infarction	 0.84	 [0.62,1.13]	 0.73	 [0.40,1.32]	Heart	failure	 0.75	 [0.55,1.03]	 1.48	 [0.82,2.67]	Peripheral	vascular	disease	 1.01	 [0.68,1.49]	 0.63	 [0.26,1.52]	Stroke	 0.99	 [0.72,1.36]	 0.73	 [0.37,1.46]	Chronic	obstructive	pulmonary	disease	 0.95	 [0.67,1.36]	 1.63	 [0.84,3.15]	Cancer	(3	years)	 0.78	 [0.43,1.40]	 1.09	 [0.38,3.14]	Known	Atrial	fibrillation	 1.34	 [0.99,1.83]	 0.89	 [0.46,1.74]	
Hospital	course	characteristics	Killip≥2	 1.06	 [0.83,1.37]	 1.49	 [0.86,2.56]	STEMI	(vs.	NSTEMI)	 1.09	 [0.84,1.41]	 1.31	 [0.73,2.36]	PCI	 0.75*	 [0.58,0.98]	 0.79	 [0.42,1.48]	CABG	 1.01	 [0.63,1.63]	 2.10	 [0.83,5.30]	In-hospital	new-onset	atrial	fibrillation	 1.03	 [0.66,1.59]	 1.20	 [0.46,3.10]	Intravenous	diuretic	use		 2.07***	 [1.63,2.63]	 0.68	 [0.40,1.17]	
Medication	on	admission	ACEi	 1.01	 [0.77,1.33]	 1.93*	 [1.15,3.26]	ARB		 0.92	 [0.67,1.27]	 1.26	 [0.67,2.35]	β-blocker		 1.02	 [0.81,1.30]	 1.18	 [0.71,1.98]	Diuretics		 1.49**	 [1.16,1.92]	 1.36	 [0.79,2.34]		
* p < 0.05, ** p < 0.01, *** p < 0.001 
Within one year following the index hospitalization, hyperkalemia was observed in 784 
(16.1%) patients. After multivariable adjustment, lower eGFR and higher discharge 
potassium were the two factors most strongly associated with a hyperkalemic event. 
Hypokalemia within one year was observed in 991 (20.4%) patients. Lower discharge 
potassium was the factor most strongly associated with a hypokalemic event (Table 6). 
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Table 6. Multivariable hazard ratios (HR) for first hyperkalemic or hypokalemic event within 
1 year post discharge. 
	 Hypokalemia	
K<3.5	mmol/L	 Hyperkalemia	K>5.0	mmol/L		 HR	 95%CI	 HR	 95%CI	
Potassium	at	discharge,	mmol/L	<3.5	 3.13***	 [2.59,3.77]	 0.83	 [0.63,1.10]	3.5-<4.0	 1.43***	 [1.23,1.67]	 0.63***	 [0.53,0.76]	4.0-<4.5	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	4.5-5.0	 0.97	 [0.77,1.23]	 1.73***	 [1.43,2.09]	>5.0	 0.95	 [0.57,1.58]	 2.40***	 [1.71,3.37]	
eGFR	strata,	ml/min/1.73m2	90+	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	60-89	 0.88	 [0.72,1.09]	 1.72***	 [1.26,2.35]	45-59	 0.76*	 [0.58,0.99]	 2.79***	 [1.97,3.94]	30-44	 0.98	 [0.74,1.29]	 4.35***	 [3.04,6.22]	<30	 1.24	 [0.92,1.67]	 7.20***	 [4.99,10.38]	
Demographics	 	 	 	 	Age,	per	10	years	 1.07	 [1.00,1.16]	 0.99	 [0.91,1.07]	Male	sex	 0.81**	 [0.71,0.93]	 1.04	 [0.89,1.21]	
Medical	history	 	 	 	 	Diabetes	mellitus	 0.97	 [0.84,1.12]	 1.54***	 [1.32,1.79]	Hypertension	 1.46***	 [1.26,1.68]	 0.89	 [0.75,1.04]	Myocardial	infarction	I	 1.03	 [0.88,1.21]	 1.04	 [0.88,1.23]	Heart	failure	a	 1.20*	 [1.03,1.40]	 1.47***	 [1.23,1.75]	Peripheral	vascular	disease	 1.20	 [0.97,1.47]	 1.29*	 [1.03,1.61]	Stroke	 1.03	 [0.86,1.23]	 0.99	 [0.80,1.22]	Chronic	obstructive	pulmonary	disease	 1.20	 [0.99,1.45]	 1.41**	 [1.15,1.74]	Cancer	(3	years)	 1.43*	 [1.09,1.89]	 2.11***	 [1.60,2.79]	Atrial	fibrillation	b	 1.31***	 [1.12,1.52]	 1.08	 [0.91,1.29]	STEMI	 0.94	 [0.80,1.12]	 1.10	 [0.92,1.31]	PCI		 0.59***	 [0.50,0.70]	 0.70***	 [0.59,0.84]	CABG		 1.51**	 [1.17,1.94]	 1.28	 [0.94,1.75]	
Medication	at	discharge	ACEi	 0.89	 [0.77,1.02]	 1.00	 [0.85,1.18]	ARB		 0.91	 [0.75,1.11]	 1.00	 [0.80,1.25]	β-blocker		 0.85	 [0.70,1.03]	 1.08	 [0.85,1.37]	Diuretics		 1.35***	 [1.15,1.57]	 1.27**	 [1.07,1.51]		
* p < 0.05, ** p < 0.01, *** p < 0.001 
a History of heart failure defined as previous heart failure history, or Killip≥2 or intravenous diuretic use during the index hospitalization.  
b History of atrial fibrillation defined as the previous atrial fibrillation history or development of atrial fibrillation during the index 
hospitalization.  
Mortality within one year of discharge was 14.8% (n=718). A U-shaped association between 
potassium at discharge and 1-year mortality was observed. This association remained after 
multivariable adjustment and was significant for plasma potassium strata <3.5 mmol/L and 
≥4.5 mmol/L. Within one year of discharge, 633 (13.0%) patients were hospitalized due to 
reinfarction, 1045 (21.5%) were hospitalized due to heart failure, and 247 (6.0%) had a new 
diagnosis of atrial fibrillation/flutter. After multivariable adjustment, no significant 
associations between discharge potassium and the latter three outcomes were observed with 
one exception; patients with discharge potassium between 3.5-<4.0 mmol/L had lower odds 
(OR 0.80, 95% CI 0.69-0.92) of becoming hospitalized because of heart failure (Table 7).  
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Table 7. Multivariable hazard ratios (HR) for potassium categories at discharge and the risk 
of death and cardiovascular outcomes within 1 year. 
	 Death	 Myocardial		
re-infarction	
Heart	failure	 De	novo	Atrial	
fibrillation												
(n=4109)	
	 HR	 95%CI	 HR	 95%CI	 HR	 95%CI	 HR	 95%CI	
Potassium	at	discharge,	mmol/L	 	 	 	 	 	 	 	 	<3.5	 1.50***	 [1.18,1.89]	 1.07	 [0.80,1.43]	 0.98	 [0.79,1.21]	 1.11	 [0.72,1.70]	3.5-<4.0	 0.88	 [0.74,1.06]	 0.98	 [0.81,1.18]	 0.80**	 [0.69,0.92]	 0.77	 [0.58,1.04]	4.0-<4.5	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	 1.00	 [1.00,1.00]	4.5-5.0	 1.25*	 [1.00,1.56]	 0.98	 [0.75,1.27]	 1.01	 [0.83,1.22]	 0.66	 [0.42,1.05]	>5.0	 1.51*	 [1.00,2.27]	 1.21	 [0.71,2.06]	 1.11	 [0.76,1.64]	 0.80	 [0.32,1.99]		
* p < 0.05, ** p < 0.01, *** p < 0.001 
a Adjusted for age, sex, history of diabetes mellitus, hypertension, myocardial infarction, heart failure, peripheral vascular disease, stroke, 
chronic obstructive pulmonary disease, cancer, atrial fibrillation, STEMI, non-STEMI, PCI, CABG and medication at discharge (ACEi, ARB, 
β-blocker and diuretics); History of heart failure defined as previous heart failure history, or Killip≥2 or intravenous diuretic use during the 
index hospitalization; History of atrial fibrillation defined as the previous atrial fibrillation history or development of atrial fibrillation during 
the index hospitalization. 
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6 DISCUSSION 
6.1 MAJOR FINDINGS 
In Study I, we found that incidence of in-hospital cardiac arrest in NSTE-ACS ranges from 
1.3% to 2.3%. For the purpose of risk stratification, we developed a user-friendly risk score 
that may be used to estimate the risk of in-hospital cardiac arrest for patients admitted with 
suspected NSTE-ACS. The risk score comprises five dichotomous variables easily accessible 
at admission: systolic blood pressure <100 mm Hg, age ≥60 years, hear rate <50 or ≥100 
bpm, ST-T abnormalities on the admission ECG, and Killip class ≥II. 
In Study II, comprising a contemporary cohort of MI cases, the incidence of OHCA within 
90 days after discharge was low (0.29%). Six variables (male sex, age ≥60 years, eGFR <30 
mL/min per 1.73 m2, Killip class ≥II, new-onset atrial fibrillation/ flutter, and LVEF 
categorized as ≥50%, 40-49%, 30-39%, and <30%) predicted OHCA as well as non-OHCA 
death better than an LVEF cut-off of 40% alone. 
For patients admitted with suspected ACS, results from Study III showed that, potassium 
disorders at admission are associated with adverse in-hospital outcomes regardless of 
presentation characteristics or final diagnosis. After multivariable adjustment, plasma 
potassium ≥5.0 mmol/L was associated with in-hospital death, plasma potassium <3.5 
mmol/L was associated with in-hospital cardiac arrest, and plasma potassium <3.0 mmol/L 
was associated with new-onset atrial fibrillation/flutter during hospitalization. 
In Study IV, we found that potassium disorders within the first year of discharge after MI are 
frequent. In our study cohort, hyperkalemia within one year was observed in 16.1% and was 
strongly associated with a lower eGFR and higher potassium level at discharge. Hypokalemia 
affected 20.4% of patients within one year and was strongly associated with lower potassium 
at discharge. Additionally, a U-shaped association between discharge potassium level and 
mortality within one year was observed and remained after multivariable adjustment. 
6.2 WHO AND WHERE TO MONITOR IN SUSPECTED NSTE-ACS? 
The coronary care unit (CCU) was introduced in the beginning of the 1960s and enabled 
continuous heart rhythm monitoring with rapid detection and treatment of life-threating 
arrhythmias by trained personnel. In the treatment of acute MI, the CCU has been considered 
the single most important advance of the 20th century91. However, given the development and 
improvement of care and outcome in ACS, the need and cost effectiveness for low-risk 
patients to be admitted to the CCU have been disputed92. Current European guidelines 
recommend that according to clinical presentation after established NSTE-ACS diagnosis, 
UA patients do not require rhythm monitoring and NSTEMI patients at low risk for 
arrhythmias may be monitored in a CCU or an intermediate care unit likewise. Low risk is 
defined as the absence of the following criteria: hemodynamically unstable arrhythmias, left 
ventricular ejection fraction below 40%, failed reperfusion, additional critical coronary 
stenoses of major vessels, or complications related to percutaneous revascularization2. Still, 
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patients with uncomplicated NSTE-ACS are commonly observed in the CCU. A Canadian 
study reported that among nearly 8000 patients with stable NSTE-ACS, almost two-thirds 
were admitted to a CCU. Compared to those admitted to a cardiology telemetry ward, clinical 
outcome did not differ93.  
At admission, the diagnosis of NSTE-ACS may not necessarily have been established. 
Additionally, several of the abovementioned criteria to define patients at low risk for 
arrhythmias may not be known. Hence, for patients admitted with suspected NSTE-ACS, the 
risk score proposed in Study I may aid in targeting those suitable for monitoring in a 
telemetry ward or a CCU. For patients at lowest risk according to the risk score, the estimated 
risk of in-hospital cardiac arrest was 0.18%. The corresponding observed incidence was 
0.17% in the derivation cohort, 0.19% in the temporal validation cohort, and 0.38% in the 
external validation cohort. Hence, using the risk score, it was not possible to find a group of 
patients at truly low risk for in-hospital cardiac arrest without need for rhythm monitoring. 
6.3 SCD EARLY AFTER MI, HOW AND WHICH PATIENTS TO CAPTURE? 
In Study II, the incidence of OHCA early after MI was substantially lower than reported in 
previous studies32,32. Importantly, we only included patients, who had undergone coronary 
angiography during the hospital course. Patients, for whom a non-invasive approach is 
chosen, are likely to be more fragile and at higher risk for adverse events. We hypothesized 
that this group of patients may not be of primary interest when risk stratification for 
arrhythmic death and possible ICD implantation is warranted because of competing causes of 
death. Still, considering that a majority of trials and registry studies were conducted in the 
1990s and early 2000s, our data may indicate that the incidence of SCD early after MI has 
declined in recent years, at least for patients for whom SCD preventive strategies may be 
most beneficial. 
Over 90% of SCD cases occur out-of-hospital94. However, SCD does not equal arrhythmic 
death. Based on autopsy findings, it has been reported that only slightly over 50% of SCDs 
are caused by arrhythmias94, 95. The problem of capturing arrhythmic death is also illustrated 
by the recent VEST trial. Five out of nine patients with a wearable cardioverter–defibrillator 
worn at time of death and adjudicated arrhythmic death (as determined by an expert panel 
blinded to the group assignments) did in fact not have ventricular arrhythmias48. 
Two landmark studies did not demonstrate a benefit of ICD therapy early after MI in patients 
with LVEF ≤35% or ≤30% because of competing causes of death34, 35. These studies were 
partly conducted in an earlier therapeutic era with lower rates of revascularization and less 
aggressive antithrombotic treatment. Furthermore, ICD implantation was performed within 
31 to 40 days after MI, whereas the risk of SCD has been shown to be highest within the first 
30 days. 
Neither did the VEST trial show an advantage of a wearable cardioverter-defibrillator over 
medical therapy alone in patients with LVEF ≤35% early after MI48. The authors have raised 
questions whether the trial was sufficiently powered and whether possible misclassification 
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may have further reduced the power. Nevertheless, based on the aforementioned trials, using 
LVEF as a standalone risk predictor of arrhythmic death is not sufficient in the early phase 
after MI. 
6.4 ADMISSION POTASSIUM LEVELS AND IN-HOSPITAL ADVERSE EVENT 
IN ACS  
Results from Study III are consistent with prior observations that normokalemia on 
admission is associated with the lowest risk of in-hospital adverse events in ACS62, 66, 67. In 
contrast to previous studies, we included a broader population comprising patients admitted 
with not only confirmed but also suspected ACS. Additionally, we adjusted for subtype of 
ACS and presentation characteristics as well as renal function. Relative risks were not 
modified by final diagnosis. However, it is worth noting that for patients with STEMI and 
admission potassium 5.0-<5.5 mmol/L, in-hospital mortality reached almost 25%. In-hospital 
cardiac arrest affected 10% of patients with STEMI accompanied by admission potassium 
<3.0 or 5.0-<5.5 mmol/L. 
Compared to the U.S. registry-based study by Goyal et al., which included only patients with 
confirmed MI, event rates in Study III were lower (6.9% vs. 2.7% for in-hospital mortality 
and 4.4% vs. 1.5% for in-hospital cardiac arrest)62. Goyal and colleagues reported that after 
multivariable adjustment, admission serum potassium <3.0 and ≥5.0 mEq/L were associated 
with in-hospital mortality and admission serum potassium <3.5 mEq/L was associated with 
the composite of in-hospital ventricular arrhythmias and cardiac arrest62. Our results are 
largely in agreement with these results but suggest that hyperkalemia at admission may be an 
even stronger predictor of in-hospital mortality than hypokalemia as this association remained 
after adjusting for important presentation characteristics. SWEDEHEART reports cardiac 
arrest only when CPR and/or defibrillation have been attempted. Patients with hyperkalemia 
were generally older and more diseased, which may have influenced CPR decisions. 
Furthermore, patients with hypokalemia and associated cardiac arrest may have had a more 
favorable outcome.  
Our finding that plasma potassium <3.0 mmol/L was associated with new-onset atrial 
fibrillation, gives further support to a possible linkage between hypokalemia and the 
occurrence of atrial fibrillation. 
6.5 THE IMPACT OF DYSKALEMIA FOLLOWING MI 
The incidence of dyskalemia following hospitalization for MI has not been frequently 
reported. Neither have RCTs on RAAS inhibitor treatment after MI provided much data on 
potassium levels during the course of follow-up. Findings from Study IV suggest that 
potassium imbalance within 1 year following MI is common, affecting almost 37% of 
patients, with potassium level and renal function at discharge being the strongest predictors. 
Since all laboratory data were extracted from actual healthcare visits, the reported incidence 
is, if anything, an underestimation. Over 90% of the patients were normokalemic at 
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discharge. Given the commonness of dyskalemia during follow up, concerns may be raised 
whether a subgroup of patients would attain benefit from closer monitoring after discharge. 
We found a U-shaped relationship between discharge potassium level and mortality within 
one year, which is in line with previous observational studies64, 67, 96. Mortality risk was 
already increased for potassium within the upper normal range (4.5-5.0 mmol/L), which has 
also been demonstrated before62, 64. 
Although associations between dyskalemia and adverse events have been repeatedly 
demonstrated in observational studies, no causal relationships have been established. Whether 
hypokalemia and hyperkalemia are in fact risk factors or merely risk markers remain 
unknown. In heart failure, Lund and Pitt argue that hyperkalemia may primarily be a risk 
marker resulting in the underuse of RAAS inhibitors, which in turn is causative of worse 
outcome97. Whether this may hold true for the MI population, which in many ways overlaps 
the heart failure population, is not clear. 
6.6 LIMITATIONS  
All studies were derived from large-sized cohorts, which reduces but does not eliminate the 
possibility of random errors. As for systematic errors, both selection and information biases 
are likely to be present in registry studies. The nation-wide SWEDEHEART registry includes 
the majority, but not all, of patients admitted with symptoms suggestive of ACS. Cross-
linkage with the National Cause of Death Register minimizes loss to follow-up. For other 
predefined outcomes, validity relies solely on collected data. In order to enable imputation of 
missing values, data was assumed to missing at random, which may not hold true. Finally, 
confounding possesses a major source of bias in non-randomized cohort studies. Although, 
multivariable adjustment and stratification were assessed, residual confounding may still be 
present.  
Specific limitations of the individual studies are discussed in brief below. 
6.6.1 Study I  
Our reported incidence of in-hospital cardiac arrest in NSTE-ACS is in agreement with 
previous studies. However, it is uncertain how well the true incidence of in-hospital cardiac 
arrest was captured considering the definition of the outcome variable and possible 
underreporting as well as missing data for in-hospital cardiac arrest and cardiac arrest prior to 
admission. The reported incidence may therefore be underestimated or overestimated. No 
data on timing of cardiac arrest or temporal relationships to revascularization were available. 
Neither were cardiac troponin measurements nor LVEF on admission available.  
The risk score did not perform optimally in the MINAP cohort. Adjusting for underlying risk 
or including complete cases only did not improve the performance. Compared to 
SWEDEHEART, the overall incidence of in-hospital cardiac arrest was higher in MINAP 
and notably patients with a non-ACS diagnosis as compared to NSTE-ACS were at equal or 
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higher risk for in-hospital cardiac arrest. In addition, one of the five variables in the risk 
score, Killip class, was missing in 70% of patients in MINAP. Although multiple imputation 
was performed, its validity may be questioned.  
6.6.2 Study II  
Comparing our results to studies using SCD, most often ascertained by reviewing medical 
records and death certificates, as an endpoint may be problematic. Moreover, not all cases of 
SCD occur out-of hospital and OHCA does not necessarily equal SCD. We chose to include 
only patients who had undergone coronary angiography during the hospital course. Hence, 
our reported results do not represent the true OHCA incidence. Furthermore, the Swedish 
Cardiopulmonary Resuscitation Registry only captures cases of OHCA, which were treated 
by EMS. 
Data was missing for several variables, most notably for the key variable LVEF. Only 
complete-case analyses were performed, and hence selection biases may have been 
introduced. Although coronary angiographic findings were evaluated in multivariable 
analyses, detailed data regarding specific PCI procedures were not available and hence not 
adjusted for. We did not have information on hospital readmissions within the follow-up 
period other than cases of reinfarction registered in SWEDEHEART, which were excluded. 
6.6.3 Studies III-IV  
In Studies III-IV, potassium concentration was measured in plasma, whereas most prior 
studies in the field were based on measurement of serum potassium. Serum potassium is 
generally slightly higher than plasma potassium98. A mean difference of 0.18 mmol/L has 
been reported99. Hence, our results are not directly comparable to prior studies reporting 
serum potassium measurement. Furthermore, Studies III-IV were restricted to patients 
residing in the Stockholm County, which could be a source of bias. 
In Study III, no temporal relationships between admission potassium measurement and 
outcomes were available. In addition, data did not allow a distinction between different types 
of diuretics at admission, e.g. loop diuretics and MRA. 
In Study IV, follow-up was based on potassium tests available within one year. Hence, 
selection bias, particularly detection bias, is likely to be present. Although we adjusted for 
medication at discharge, data on continuation or discontinuation of medical therapy during 
follow-up were not taking into account except for MRA.  
6.7 FUTURE PERSPECTIVES  
The risk score presented in Study I may help the clinician to assess risk of in-hospital cardiac 
arrest and level of surveillance needed for patients admitted with suspected NSTE-ACS. Still, 
further validation in different populations is needed. Additionally, temporal distribution of in-
hospital cardiac arrest warrants further investigation. Future research is called for to develop a 
risk-score model identifying patients at truly low risk for in-hospital cardiac arrest. 
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Reliable risk stratification tools for SCD early after MI are lacking and further studies are 
indeed warranted. LVEF has not been proven a useful stand-alone predictor. As shown in 
Study II, five clinical variables in addition to LVEF predict OHCA but also non-OHCA 
death better than LVEF alone. An ideal risk stratification test would identify patients at high 
risk for arrhythmic death and low risk for non-arrhythmic death so that preventive strategies 
(e.g. ICD or wearable cardioverter–defibrillator) may safely and cost-effectively be 
implemented.   
Results from Studies III-IV confirm that potassium imbalance is associated with adverse 
outcomes. Our findings suggest that patients admitted with suspected ACS or discharged 
after MI and who have concomitant potassium imbalance should be closely monitored. 
However, whether dyskalemia represents a risk factor or merely a risk marker remains 
unclear. Large interventional trials taking the full range of potassium disturbances into 
account and randomizing patients to different potassium targets will never be conducted. 
Still, several studies, including our own, have demonstrated an association between mild 
hyperkalemia or even potassium in the upper normal range and adverse events. Randomized 
trials in this setting might be feasible. Furthermore, novel potassium binders have recently 
been introduced and warrant further investigation100, 101. 
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7 CONCLUSIONS 
A simple points score comprising five variables readily available on admission (systolic 
blood pressure, age, heart rate, ST-T changes on ECG, and Killip class) may be used to 
predict in-hospital cardiac arrest in patients admitted with suspected ACS. 
In our cohort of MI patients, six variables (sex, age, eGFR, Killip class, new-onset atrial 
fibrillation/ flutter, and LVEF) predicted OHCA as well as non-OHCA death within 90 days 
after discharge better than an LVEF cut-off alone. 
Hyperkalemia at admission is associated with in-hospital mortality and hypokalemia is 
associated with in-hospital cardiac arrest and new-onset atrial fibrillation/flutter in patients 
admitted with suspected ACS irrespective of baseline characteristics or final diagnosis. 
Within the first year following MI, hyperkalemia and hypokalemia are frequently 
encountered. Potassium level and eGFR at discharge strongly predict their occurrence as well 
as one-year mortality. 
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“Prediction can be very difficult, especially about the future.” 
Danish saying 
